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To Max

”Men alltid reste sig ett nytt krön i hans synfält. Oändlighetsfjäll. Stenvåg efter 
stenvåg. Dvärgbjörk och kråkris. Här och där en trädknota med stelnad vindjäm-
mer i. Varenda fjällbjörk var vriden som en utsliten käring. Vilket jävla liv. Vilket 
vindplågat ljussnålt marigt helvete.”
Kerstin Ekman ur Sista rompan
“It’s a universal law- intolerance is the first sign of an inadequate education. An 
ill-educated person behaves with arrogant impatience, whereas truly profound 
education breeds humility.”
from August 1914 by Aleksandr I. Solzhenitsyn 
Translated by H.T. Willetts

ABSTRACT
Allergic rhinitis (AR) deprives work capacity, social activities and quality of life, 
and costs the Swedish society about €1.3 billion annually. Allergen-specific immu-
notherapy (AIT) amends the symptoms and improves the course of the  disease. 
The symptom ameliorating effects last several years after the discontinuation 
of treatment. The golden standard for immunotherapy of AIT is subcutaneous 
administration but during the last decade sublingual immunotherapy has become 
common. Both forms of AIT are underused due to the lack of knowledge about the 
treatments among physicians, lack of access to the treatment and inconvenience 
for the patients. Intralymphatic immunotherapy (ILIT) is an emerging form of 
AIT, which requires only 3 injections during a period of 8 weeks. 
The aim of this thesis was to evaluate the intralymphatic route by using  different treat-
ment protocols and to characterize immunological signs of tolerance development.
In paper I, asthmatic young adults were treated in a randomized double-blind 
placebo-controlled (RDBPC) trial with three intralymphatic injections of birch 
or grass allergen in doses of 1000 SQ-U, or placebo. The active group returned 
the next year for a booster injection. The treatment was safe, even in patients with 
mild asthma. The use of symptom relieving medications at the pollen season was 
reduced the first and the second year after treatment. The allergen specific IgG4 
antibodies were increased 6-9 months after treatment. The asthma symptoms could 
not be improved among well-treated patients. 
In paper II, polysensitized patients received ILIT for both birch and grass induced 
AR in a RDBPC trial, with doses of 1000 SQ-U each, in three injections. The 
treatment was safe, even with two allergens given simultaneously. The rhinocon-
junctivitis symptoms after a nasal provocation test were improved 6-9 months after 
treatment and the use of symptom relieving antihistamines and/or nasal steroid 
spray was reduced. The timothy specific IgG4-levels, regulatory T-cells (Tregs) 
and Th1 type of T-cells were increased in blood and the effector memory T-cells 
were increased in the lymph nodes after treatment. 
In paper III, ILIT in up-dosing schedules were evaluated in two RDBPC trials. In 
ILIT after SCIT-10 000, patients that had recently received SCIT for grass AR, 
were treated with 1000- 3000- 10 000 SQ-U of grass allergen, with one-month 
intervals. The treatment was safe. The combined symptoms and medication scores 
(CSMS) were improved during the pollen season after treatment and the timothy 
specific IgG4 levels were increased. In ILIT de novo- 3000, patients with grass 
induced AR without previous AIT were recruited. The dose-escalation was safe 
up to 3000 SQ-U, but serious anaphylactic reactions occurred at 5000 SQ-U. The 
patients that were treated with the modified protocol 1000-3000-3000 SQ-U did 
not improve the AR symptoms at pollen season and had no clear signs of beneficial 
immunologic changes in blood or lymph nodes.
In paper IV, the patients that were treated with active ILIT 5-6 years previously in 
paper II, returned for an open follow-up and were compared to a non-AIT treated 
control group. The symptoms at NPT were unchanged, but the CSMS at the pollen 
season was lower compared to in the control group. Timothy specific IgE levels 
had decreased markedly compared to before treatment, IgG4 was still slightly 
elevated and the lymph node samples displayed increased levels of memory T-cells. 
In summary, ILIT with 1000 SQ-U was safe with mild asthma and when given with 
two allergens concomitantly. Up-dosing to 10 000 SQ-U was safe among previously 
SCIT-treated patients, but dose-escalation to 5000 SQ-U induced anaphylaxes in 
de-novo patients and should not be performed. The AR symptoms were improved 
after 1000 SQ-U and after up-dosing to 10 000 SQ-U among SCIT-treated patients, 
but up-dosing to 3000 SQ-U failed to improve the clinical symptoms in previously 
unvaccinated patients. Early immunological changes included increases in timothy 
specific IgE and IgG4 levels, Treg and Th1 levels in blood and an increase in the 
number of EM T-cells in lymph nodes. Long term changes noted were reduced 
specific IgE levels in blood and an increased number of memory T-cells in lymph 
nodes, as signs of a possible long-term treatment effect.
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11 AIMS
Intralymphatic immunotherapy (ILIT) has been proposed as a fast and safe alter-
native to conventional allergy immunotherapy. The intention of this thesis was 
to evaluate the intralymphatic route by using different treatment protocols and to 
characterize the immunological changes induced. More specific to:
- Study the safety of ILIT in three new situations; among young adults with 
mild asthma, when using two concomitant allergens and when increasing the 
doses of the allergens given
- Evaluate the effects of ILIT on allergic asthma
- Assess the clinical symptom improvements in a one-seasonal perspective, 
using two concomitant allergens
- Explore if an increase of the doses given improves the therapeutic outcome
- Investigate if the positive effects of ILIT remain 5-6 years after the vaccination 
- Characterize immunological changes that could signal induction of tolerance 

32 INTRODUCTION
2.1 Allergic rhinoconjunctivitis
The incidence of allergic rhinoconjunctivitis (AR) is increasing and today up to 
40% of the younger population in westernized countries are affected. This increase 
has not yet shown signs to decline and the reasons for this almost epidemic evolve-
ment are not fully understood. Worldwide around 500 million people are affected 
(1). Symptoms include runny and blocked nose, sneezing, nasal and ocular itching, 
red and watery eyes. In addition, although often not as well acknowledged, these 
patients suffer from inflammatory fatigue as well as tiredness due to impaired sleep 
(2).The disease substantially impacts the patients’ quality of life and capacity at 
work or school (1, 3). Further, the disease is costly for the society. In Sweden, a 
population of less than 10 million inhabitants, it has been estimated to costs €1.3 
billion annually (4). The surprisingly high cost is not only due to absenteeism, 
but to a large extent also due to low performance while at work (presenteeism). 
AR is an IgE (immunoglobulin E) -mediated disease that is caused by B-cells 
overproducing IgE antibodies that reacts upon common environmental antigens 
called allergens. Allergens are most often proteins in e g pollen or food. IgE gets 
attached to the surfaces of mast cells and basophil cells that often reside in nasal 
and ocular tissue. When IgE antibodies on the cells encounter its specific allergen 
a signal through the receptor FcεR1 results in a discharge of allergic mediators in 
the tissue, e g histamines. This causes local symptoms such as itching and swelling 
with rapid onset, called the immediate reaction. The histamine and other mediators 
cause a late-phase allergic reaction with recruitment of other inflammatory cells, 
such as T-cells and eosinophils, to the site (1).
Figure 1. Sensitization at the development of AR. By unknown mechanisms, plasma cells 
start to produce IgE antibodies toward harmless substances, e g pollen. The IgE antibodies 
are secreted into blood and get attached to mast cells in the mucosa. At a later encounter 
with the allergen, the IgE antibodies crosslink their receptors on the mast cells. This acti-
vates the cell and causes degranulation of preformed vesicles containing e g histamine, 
which causes rhinoconjunctivitis symptoms at the immediate reaction. At the late reaction, 
inflammatory cells migrate to the mucosa and cause inflammation. 
42.2 Seasonal allergic rhinoconjunctivitis
Seasonal AR is caused by intermittent exposure to allergens with duration of symp-
toms per definition not exceeding one month (1). However, in Northern Europe, 
a poly-allergic patient can experience peak allergic symptoms in May for birch 
pollen and later in June for grass pollen, with sometimes overlapping seasons 
and therefore, fulfilling criteria for perennial AR. In fact, the pollen season starts 
already in February with birch cross-reactivity to alder and hazel trees. If allergic 
also to ragweed, allergen exposure can proceed to the end of October. There are 
increasing reports that due to climate changes and urbanization the flora is chang-
ing. This causes spreading of allergens such as cedar tree in South East Asia (5) 
and ragweed in Northern America (6). Climate changes have been the cause of a 
prolonged vegetation period in tempered regions and therefore a longer period of 
allergen exposure (7). 
First line treatment for mild AR is antihistamines or leukotriene receptor antago-
nists which often give good symptom relief (8). If the patients experience trouble-
some symptoms the disease is classified as moderate or severe according to the 
ARIA guidelines (1). Intranasal corticosteroids should then constitute the base of 
the treatment. However, even when adding cromoglycates or ipratropium, many 
patients still do not come near full symptom relief. Systemic steroids offer reliable 
but temporary halt of allergic symptoms and are considered as the last “rescue” 
option (1). Anti-IgE treatment with Omalizumab® improves symptoms effectively 
and has an acceptable safety profile but will not likely become a widespread treat-
ment due to its high cost (9). Hence, there is an urgent need for development of 
new effective treatments.
2.3 Allergy immunotherapy
Today, the only causative treatment for AR is allergy immunotherapy (AIT). The 
therapy was first described in 1911 when Noon and Freeman inoculated extracts 
of grass pollen in order to allow the immune system to develop tolerance to the 
allergen (10). Today the extracts used for treatment are standardized with a defined 
concentration of the major allergens often administered in the form of subcutane-
ous injections (SCIT) and sublingual tablets (SLIT).
2.3.1 SCIT
The golden standard for the treatment of AR in Europe is subcutaneous immuno-
therapy (SCIT) (11, 12). It should be considered for moderate to severe AR (1). 
Studies have demonstrated that SCIT improves nasal/ocular symptoms and reduces 
the need for medication. The improvement of symptoms has been described to 
last up to 8 years after the end of the vaccination period (13). SCIT also improves 
5quality of life (13) and prevents progression of AR to asthma, at least in the short 
perspective (14-16). Some studies have indicated prevention of additional sen-
sitizations (17, 18) but recently the evidence for long term protective effect has 
been debated (19). 
The allergen that is identified as the trigger of the AR symptoms is injected sub-
cutaneously, usually in the upper arm. The injections are repeated with increasing 
doses every 1-2 weeks during an up-dosing phase of 7-15 injections. The patients 
return for maintenance injections every 6-8 weeks during 3-4 years (13). This 
means SCIT is a time-consuming treatment which is inconvenient for the patients. 
Furthermore, even though SCIT is considered to be a cost saving treatment in the 
long run, with decreased loss of workdays and lower drug costs after therapy, the 
treatment is costly for the healthcare providers(20). In practice, it is considered 
only for patients with severe allergic symptoms for allergens that cannot be avoided 
and when conventional pharmacological treatment is insufficient. The allergen 
injections also convey a risk of allergic reactions such as local erythema, oedema 
and pruritus at the injection site, airway obstruction, nasal or ocular symptoms or 
urticarial rash. Anaphylactic reactions are rare but can occur (21), which is why 
the treatment in Sweden is preferably given at hospitals (22). 
2.3.2 SLIT
During the last decades, sublingual administration (SLIT) has been developed as 
an alternative to SCIT. The patient takes one tablet under the tongue every day 
for three years. Advantages are that the risk of allergic side effects and the need 
for medical supervision are substantially lowered (23). Indirect comparisons 
between SCIT and SLIT suggest that the clinical effect of SLIT is at least close 
to the effect of SCIT (24). A disadvantage of SLIT is that the treatment time still 
lasts for 3 years, which understandingly causes problem with long term patient 
adherence (25, 26). Some studies have reported that only 44-46 % of the patients 
that are prescribed SLIT continue treatment after the first year (27, 28). Also, some 
patients experience disturbing local side effects during the first period of the treat-
ment (29). So far, three allergens are available for SLIT therapy in Europe, grass, 
house dust mite and birch. 
AIT is an expensive treatment in relation to the poor compliance in SLIT, high 
cost for the medical product, and is resource demanding with the need for medical 
supervision (SCIT) (30). Nevertheless, AIT is cost-effective by lowering the costs 
for pharmacotherapy and reducing the burden of uncontrolled disease in the society 
as a whole (12, 30, 31). Despite all positive effects AIT remains underused, likely 
due to safety concerns, issues with efficacy, and the long treatment regimens (13). 
Hence, there is a great incentive to find new ways to shorten the duration of AIT 
without losing the good effect or jeopardizing the safety.
62.3.3 New strategies for immunotherapy
2.3.3.1 Other administration routes
Alternative routes of allergen delivery have been explored to stimulate allergen 
uptake by antigen presenting cells and to avoid needle injections. Nasal admin-
istration by placing allergen on the nasal mucosa once weekly for 4 months has 
improved rhinitis symptoms, but induced bothersome local side effects for some 
patients (32). By placing allergen-adsorbed patches on the skin surface after 
the outer layers of the skin have been stripped by adhesive tape (epicutaneous 
administration) amelioration in seasonal rhinitis symptoms were obtained but also 
resulted in local and systemic side effects (33-35). Intradermal injections with low 
doses of grass allergen did not elicit any systemic reactions and late cutaneous 
responses were reduced (36). The authors speculate that the immune modulating 
effect despite the low allergen doses could be attributed to effective draining of 
allergen from the dermis to the lymphatics with aid from the antigen presenting 
Langerhans cells. 
2.3.3.2 Adjuvants
Another approach to enhance the effect of immunotherapy is the use of adjuvants. 
Alum is the most widely used adjuvant for SCIT. The effect is mediated by a slow 
release of allergen, which prolongs the allergen presentation time (37). One side 
effect is the risk of developing alum contact allergy with itching noduli at the injec-
tion site. Possible bioaccumulation with long-term disease development have been 
discussed but have not been found clinically (37). Other adjuvants such as Toll-
like receptor agonists and monophosphoryl lipid A (MPL) may further improve 
the outcome (38), but are still in the development phase.
2.3.3.3 Allergoids, peptide vaccines and recombinant allergens
In order to reduce the risk of allergic reactions the allergen can be modified. By 
processing the allergen chemically, allergoids can be produced that are less likely 
to induce reactions upon use, but still modulate the immune system. In Pollinex® 
Quattro, MPL and another adjuvant, microcrystalline tyrosine, is coupled to pollen 
allergen modified with glutaraldehyde and given as four pre-seasonal subcutaneous 
injections (39).
Another way of decreasing the potential for side-effects is to change the allergen 
protein structure by either creating recombinant proteins and/or cutting the proteins 
into peptides targeted to stimulate B- or T-cells (38, 40, 41). An open label study 
of a peptide derived from the Lolium perenne grass showed promising results with 
inhibited reaction in conjunctival provocation testing after 6 weeks of treatment. 
The use of MB32, a peptide from the IgE-binding site of grass allergen that is 
7fused to a carrier protein from Hepatitis B virus, is being developed to stimulate 
tolerogenic T-cell signals. An early trial showed that three subcutaneous injections 
could be performed without any early or late severe adverse allergic reactions and 
the nasal provocation test (NPT) in an allergen chamber showed reduced symptoms 
(42). A subsequent RDBPC trial that investigated MB32 in six injections during 
two years showed that the treatment reduced medication use and improved the 
scores at the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), increased 
the allergen specific IgG levels without increase in IgE levels, but could not verify 
improvement in combined symptoms and medications scores (CSMS).
Although some positive and interesting results for the use of allergoids and pep-
tide vaccines have been produced, it appears as these tentative approaches in AIT 
still have several hurdles to pass and a long way to go before reaching the clinic 
(40). With increasing insights in the mechanisms behind AIT many new types of 
modified allergens can be generated. Nonetheless, it is often difficult to translate 
promising results from early phase trials to robust therapies with improvement of 
symptoms in a real life setting (43) and a high cost for the vaccines for the devel-
opment might limit the use.
2.4 Intralymphatic administration 
2.4.1 Rationale 
According to the “geographical concept of immune reactivity” an immune response 
can only be elicited with the antigen being inside secondary lymphoid organs such 
as the lymph nodes or the spleen (44, 45). The proposed mechanism behind tol-
erance development in AIT is that allergen has to be transported to lymph nodes 
where it can interact with T-cells and B-cells (45). A problem with SCIT is that the 
subcutaneous tissue contains low levels of antigen presenting cells which means 
that high doses of allergen must be used. There are also mast cells located in the 
tissue which confers a risk of allergic reactions.
By injecting an antigen directly into the lymph node, the immune system can be 
stimulated much more efficiently. The lymph nodes constitute an immunologically 
active system with high concentrations of antigen presenting cells such as dendritic 
cells (DCs) and B-cells. This increases the chances of interaction between the anti-
gen and the specific T-cell. Lymph nodes contain low numbers of mast cells and 
basophils, which theoretically makes allergic hypersensitivity reactions less likely. 
Biodistribution studies of intralymphatic and subcutaneous injections in mice (46) 
and humans (47) have shown that only a small fraction of subcutaneously injected 
proteins (e. g. allergens) reaches the lymph nodes. Most of the protein is drained to 
the liver where it is degraded, and a smaller proportion reaches the lymph nodes. 
8In one experiment the same dose of protein was injected in a lymph node and in 
the subcutis (47). After 25 hours the targeted lymph node and the adjacent nodes 
still contained a high concentration of protein. The draining lymph nodes close 
to the subcutaneous injection only had low levels of proteins 20 minutes and 25 
hours after injection. 
There are only few studies of ILIT in animals. One study showed that mice sen-
sitized to cat fur were protected against anaphylaxis after intralymphatic allergen 
injections but not after subcutaneous ditto (46). Two trials showed that some 
dogs, but not all, with atopic dermatitis improved after receiving ILIT (48, 49). 
ILIT as primary prevention in horses induced favourable IgG antibody responses 
but the horses were not followed up to determine if they developed allergy (50, 
51). Some mild local reactions were reported in the animal studies but no severe 
adverse events.
Figure 2. Ultrasonography picture of a lymph node, with a hypoechoic (dark) cortex and a 
central echogenic (light) hilum. Long arrow: Lymph node. Short arrow: Needle for injec-
tion. Asterix: Tip of the needle.
2.4.2 Human studies
The first clinical study in humans was an open randomized study where 58 patients 
received ILIT with grass allergen. After one and three years the ILIT-patients 
reported the same level of symptom relief as the patients that were allocated to 
SCIT (52). Other open studies include a trial of 7 patients treated with grass-ILIT 
that reported increased thresholds at NPT and skin prick test (SPT) and induced 
allergen specific plasmablast cells (53) and a trial of 10 patients also receiving 
grass-ILIT with reduced rhinitis total symptom scores (RTSS) and RQLQ scores 
(54). One recently published study from China treated 98 patients with AR induced 
by house dust mite, with allergen injection into cervical lymph nodes. Despite the 
sensitive location there were no serious local or systemic adverse reactions, and 
the authors found reduced RTSS and improved RQLQ scores (55). Another open 
9study used mixtures of house dust mite and animal dander allergens in up-dosing 
regimens, which gave good subjective symptom relief (56). In this study systemic 
and even anaphylactic reactions were reported, all other studies have demonstrated 
a good safety profile. In a recent open grass-ILIT study with a randomized booster 
injection the year after basic treatment, there were no significant improvement in 
CSMS but the specific IgG4 levels were increased (57).
Five randomized double-blind placebo-controlled (RDBPC) ILIT studies have been 
published. One trial evaluated ILIT with cat allergen. The recombinant allergen 
was modified with the allergen fused to an intracellular transporter molecule. This 
reduced the nasal reactivity upon allergen provocation and increased cat-dander 
specific Immunoglobulin G4 (IgG4) antibodies (58). Our research group showed 
that ILIT with birch or grass allergen improved symptoms at pollen season. It was 
a placebo controlled trial with 7 active patients (59), later expanded to 21 patients 
(60). The patients that had improved NPT also had increased allergen specific IgG4 
affinities. A Danish grass-ILIT trial with 30 active patients could not verify any 
clinical effect (61). Treatment was given with a shorter dose interval (1-2 weeks 
instead of 4 weeks), which could have an impact on the immunological effect (62). 
ILIT with grass pollen in an up-dosing schedule in young adults showed improved 
symptoms scores at pollen season although not statistically significant in the small 
cohort of 7 active and 8 placebo patients (63). In a recently published study, patients 
were randomized 2:1 to receive ILIT with Japanese cedar pollen or placebo. The 
active group reduced reactivity at NPT and improved VAS. This trial remained 
blinded for three years and showed a sustained clinical effect for 1-2 years (123). 
To summarize, nine out of ten human ILIT trials, not including the trials presented 
in this thesis, have shown results supporting the concept of ILIT. Two studies used 
dose-escalation protocols. Half of the studies used a study design with RDBPC 
measures. One of these included a follow up longer than the first season. Different 
extracts have been used regarding allergens and preparations, according to local 
relevance and availability of allergens. 
2.5 Immunology in allergy 
The immune system consists of biological processes and structures that have evolved 
to protect the body from disease and have to mount balanced responses to a wide 
range of pathogens. In AR, there is a pathologic response towards harmless anti-
gens, that has many similarities with the normal Th2 response seen upon infection 
with extracellular parasites. This includes activation and differentiation of T-cells 
of Th2 type, IgE- producing B-cells, mast cells, basophils and eosinophils (64). 
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2.5.1 Inflammatory cells of the immune system
All cells of the immune system begin as bone marrow stem cells. These differenti-
ate into lymphoid progenitor cells and later become lymphocytes (T-cells, B-cells, 
natural killer cells (NK) cells) or myeloid progenitor cells that differentiate into 
monocytes, granulocytes and erythrocytes.
2.5.1.1 Dendritic cells 
When an antigen enters the body, the antigen presenting DC is the first cell that 
encounters the antigen. DCs originate from monocyte-like cells that migrate to the 
skin and mucosa. The main task of the DC is to take up and process pathogens, 
present antigens to T-cells and activate T-cells. Other antigen presenting cells in 
the skin and mucosa are monocytes and macrophages. DCs play a pivotal role at 
signalling the differentiation of T-cells (65). Immature DCs get activated either by 
cytokines (peptides used for cell signalling) from other leucocytes, or by  recognizing 
foreign substances direct through pattern recognition. The activated DC take up 
small fragments of the antigen and travels via lymph vessels to a lymph node. 
Here the DC presents small peptides of the processed antigen to T-cells. There are 
two pathways for this presentation, major histocompatibility complex (MHC) I 
and MHC II. Extracellular, engulfed, substances are presented on MHC II, lead-
ing to activation of CD4+ cells, T helper cells, which helps clearing extracellular 
infections. At an intracellular infection, substances produced inside the DCs are 
presented on MHC I molecules and signals an activation of CD8+ T-cells, cytotoxic 
T-cells, that helps removing infected cells.
2.5.1.2 T-cells
Precursor thymocytes travel from the bone marrow to the thymus where the cells 
rearrange their T cell receptors and upon successful recognition of MHC/HLA class 
II or class I acquire their specific T-cell lineage markers, CD4 and CD8 respectively. 
After a proofreading in the thymic medullae, where autoreactive thymocytes are 
eliminated, naïve T cells leave the thymus and travel through the blood stream to 
secondary lymphoid organs, i.e., lymph nodes and spleen. 
When a naïve T-cell in the lymph node encounters a peptide presented by the MHC 
molecule recognized by the unique TCR (T-cell receptor) , along with second co-
stimulatory signals, the T-cell is activated.
 When CD4+ T-cells get activated, they proliferate, give activation signals to B-cells, 
and regulate other immune responses by secreting different mediators (66). Which 
type of mature T-cell the naïve T-cell develops into, depends on local cytokines 
and other factors. Cytokines like IL-2, TGF, IFN and IL-12 drive the development 
into Th1 cells. Other cytokines like IL-4 drive the development into Th2 cells. 
Thymic stromal lymphopoietin (TSLP) influences DCs to activate towards more 
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Th2 cells (67). Depending on which cytokines the CD4+ T- cell in turn expresses, 
it is classified as a Th1, Th2 or Th17-cell important for defence in infections, 
regulatory T-cells (Treg) important for maintaining tolerance to self-antigens or 
follicular T-cells (fTh) that reside in lymphoid organs and activate B-cells (68, 69). 
Th1 cells express the transcription factor T-bet and produce IFN-γ and TGF-β in 
response to intracellular pathogens and in non-allergic subjects towards allergens. 
IFN-γ stimulates cytotoxic T-cells in the defence from intracellular pathogens. 
IFN-γ also keep up the production of Th1 cells and suppresses the differentia-
tion of T-cells into Th2 and Th17 cells (70). The allergen specific Th1 levels are 
increased in non-allergic subjects compared to allergic patients, and the increased 
fraction of Th1 can suppress Th2 pathways and the development of allergy (71). 
T-bet suppresses GATA-3 expression and Th2 differentiation (72). 
Th2 cells express the transcription factor GATA-3 and produce interleukin (IL)-
4, IL-5 and IL-13 that are involved in the clearance of extracellular pathogens. 
Th2 cells also mediate B-cells’ switch in antibody production towards IgE and 
promote survival of eosinophils. In addition, GATA-3 suppresses production of 
cytokines that stimulate Th1 cells (72). IL-4 blocks the Th1 T-cell activation and 
maintains Th2 polarization (68).
By this, the Th1 and Th2 cells often act together in inflammatory reactions but 
when a pathway becomes dominant, as when the Th2 pathway gets exaggerated 
in AR, feedback loops of cytokines maintain the unbalance. 
Th17 cells protects against bacterial and fungal infections and may have autoim-
mune properties, increase eosinophil recruitment but may also reduce neutrophil 
infiltration in asthma. Th22 independently express IL-22 and low amounts of 
IL-17, and play a role in atopic dermatitis (73). 
Treg cells are paramount to maintain tolerance to self-antigens and commensal bac-
teria. In allergy, two types of Treg cells modulate the immune system. CD4+CD25+ 
innate Tregs that express the transcription factor FOXP3, and inducible IL-10 
secreting type 1 Tregs. High levels of TGF-β, retinoic acid and short fatty acids 
promote Treg activity. Tregs suppress inflammation by production of IL-10, and 
by direct inhibition of cells e g DCs. The Treg function may be impaired among 
allergic patients (72). Induction of Treg cells is a key event in restoring the toler-
ance in allergy(73).
2.5.1.3 B-cells 
B-cells secrete immunoglobulins that neutralizes extracellular microbes, and in 
allergy produce IgE antibodies. The B-cell is produced in the bone marrow as a 
pre-B-cell and then become a mature naïve B- cell without the influence of antigens. 
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The naïve B-cells express IgM and IgD on the surface. Each B-cell recognizes 
and reacts to only one specific antigen and the total B-cell population together can 
identify virtually all antigens the body might encounter. The naive B-cell circulates 
through the lymphatic system, prepared to meet its cognate antigen. B-cells that 
do not encounter its specific antigen die unactivated (67). 
For activation of B-cells a signal from an antigen specific CD4+ T-cell is needed to 
initiate cytokine production and gene expression. After the activation, the B-cell 
may differentiate to a long lived memory B-cell or proliferate to an immunoglobu-
lin secreting plasmacell (74). The memory B-cells facilitate a quick response with 
a rapid build-up of antibody production at a subsequent encounter with the same 
antigen. 
After activation, the B-cells undergo somatic hypermutation and by this rearrange 
the heavy chain DNA with maturation of the affinity of the antibodies, and with a 
change in Ig subclasses to IgA, IgG or IgE. The antibodies circulate to detect their 
antigen and mount humoral responses, except IgE that mostly binds to the high 
affinity receptor at the surface of mast cells and basophils. B-cells also function 
as antigen presenting cells and can secrete immunomodulatory cytokines with 
effects on the activation of T-cells and DCs (66, 67).
2.5.1.4 Mast cells and basophil granulocytes
Mast cells are granulocytes that are produced in the bone marrow and then travel 
to the skin and mucosa, where they can react upon antigens. IgE antibodies get 
attached to mast cells’ FcεR1 and when IgE binds to its antigen, the receptor 
crosslinks with subsequent degranulation of the mast cells containing histamine 
and other inflammatory signals which attract e g eosinophils. 
Basophils are one of the least common leucocytes in blood. They mature in the 
bone marrow and enter the circulation where they bind to IgE which crosslinks 
the receptors in a similar fashion as mast cells. The binding of IgE competes with 
IgG4. Basophils have long been thought to only have reactive properties but is now 
acknowledged to, under the influence of IL-3, secrete IL-4  that in turn favours 
Th2 responses (67, 75, 76). 
2.5.2 Allergic type 1 reactions
Allergic rhinioconjunctivitis is an IgE mediated typ 1 reaction. There are also other 
types of allergic reactions; type II reactions with immunoglobulin binding and 
complement activation, type III reactions involving immune-complexes and type 
IV reactions mediated by T-cells rather than antibodies. They are not discussed 
further in this thesis.
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In type I reactions, antigen presenting cells such as DCs and macrophages constantly 
scan the environment and engulf peptides, presenting them to T-cells. Sensitization 
occurs when an allergen is presented to a naïve allergen specific T-cell and this 
leads to activation of the T-cell which differentiate into a Th2 cell, which then 
undergoes clonal expansion. Th2-cells produce IL-4 and IL-13 that induce naïve 
B-cells to class switch antibody production towards IgE. Some B-cells become 
IgE+ memory B-cells. Which signals that start the sensitization process are still not 
fully understood but they involve underlying genetic and environmental factors and 
Th2-cell activation under the presence of IL-4. When IgE is secreted it attaches to 
the high affinity receptor FcεR1 and sensitizes mast cells and basophil cells (77). 
An immediate type 1 reaction occurs when basophils or mast cells are exposed to an 
allergen. The allergen binds to IgE, the receptor crosslinks and the cells degranulate 
and release anaphylactogenic mediators that cause the classical symptoms of AR 
(73). The cytokines from the granules can cause a subsequent late phase reaction 
when the Th2 cells produce cytokines like IL-4, IL-5, IL-9, IL-13, CCL5. These 
cytokines increase endothelial cell adhesion, migration of cells to the inflammatory 
site and increase activation of eosinophils. Th2 cytokines also stimulate B-cells to 
keep on with its production of IgE. Allergen specific Th2-cells that are reactivated 
expand clonally and migrate to the site of the allergen encounter, contributing to 
the late phase reaction. DCs and basophils both enhance the Th2 response (73).
2.5.3 Allergy immunotherapy
At AIT, much higher doses of allergen is used than seen during natural allergen 
exposures. Although intense research has been seeking for the answer to how this 
signals development of tolerance, a clear causal mechanism has not been estab-
lished. A diverse set of immunological reactions have been observed at successful 
AIT, some connected, some seems to react in parallel. 
2.5.3.1 Early desensitization
Very early protective events at AIT include the rapid desensitization of basophils 
which get less susceptible to degranulation (20). This happens within hours after 
the first allergen administration in AIT. One proposed mechanism is related to 
the rapid upregulation of histamine receptors that counteracts the crosslinking of 
FcεR1, preventing its degranulation (78). The inactivation of basophils and mast 
cells have subsequent effects on T-cells and DCs.
2.5.3.2 T-cells
AIT also induces marked effects on allergen specific T-cells. As discussed previ-
ously, in allergic disease, the T-cell balance is skewed towards Th2 activation. At 
AIT, the T-cell balance is restored towards increased levels of T helper (Th) type 
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1 and regulatory T (Treg) cells and reduced amounts of IL-4 secreting Th2 cells. 
The mechanism by which Tregs are activated is not fully elucidated. Tregs have 
various allergen specific immune suppressive functions (73). There is a strong 
correlation between the number of Tregs induced and clinical improvement after 
AIT (20). Tregs suppress DCs by contact inhibition which suppresses the genera-
tion of the effector T-cells Th1, Th2 and Th17. In addition, Tregs produce IL-10 
that suppress IgE production of B-cells and enhance a class switch to blocking 
IgG antibodies and in particular IgG4. Allergen specific IgG4 compete with IgE 
in binding to the receptors at basophils and mast cells and prevents activation and 
degranulation. Tregs also secret TGF-β which maintain enhanced Treg production, 
and suppresses basophils’ and mast cells inflammatory functions (45).
As signs of T-cell adaptations, one ILIT study presented decreased levels of Th2 
cells and increased Treg cells and IL-10 levels in blood during ILIT, but the levels 
returned to normal after the treatment (54). An ILIT trial with a modified cat aller-
gen showed increased activation of T-cells shortly after treatment but unresponsive 
T-cells to allergen 1 year after treatment (79). An ILIT study that investigated a 
shorter dose interval could not detect any clinical effect and the immunological 
investigations showed reduced levels of interferon-γ (IFN- γ) (61), which could be a 
sign of unfavorable T-cell responses, as an immunological explanations to the result.
Figure 3. Overview of Treg and Breg (Br1) functions. Red arrows indicate suppression of 
allergic inflammation. Adapted from Akdis, World Allergy Organization Journal, Volume 
8, 2015, 17. 
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2.5.3.3 B-cells
Early in AIT there is often a rise in allergen specific IgE levels (Fig. 4). The levels 
are then gradually decreased during the treatment, but the symptom improving 
effect is not dependent on this decrease, that occurs relatively late during treatment. 
Later tolerogenic events in AIT include the induction of regulatory B-cells that 
secrete IL-10 which suppresses CD4+ effector inflammatory functions and promotes 
IgG4 production in B-cells (20, 73). A naturally occurring tolerance induction is 
observed among bee-keepers and cat owners. Allergen specific Breg cells that 
produce IL-10 and a subsequent increase in allergen specific IgG4 has been found 
among bee-keepers that have developed a natural tolerance to bee venom (80). 
Some previous ILIT trials have reported increased levels of allergen specific 
IgG4 levels (56, 58) with associated symptom improvement. In one study the 
IgG4 levels were unchanged, but an increased affinity was found in the subgroup 
that exhibited improved response to NPT (60). One ILIT trial could not verify 
any increased IgG4 production but as an indirect sign of B-cell modulation, an 
increase in plasmablasts not producing IgE was seen(53). 
Figure 4. The timing of tolerogenic events after allergy immunotherapy. From Akdis, 
World Allergy Organization Journal, Volume 8, 2015, 17. 
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2.5.4 Immunologic mechanisms in ILIT
Immune responses are initiated in secondary lymphoid organs, it therefore seems 
to be a good chance for efficient stimulation when the allergen is injected into 
the nodes. They contain high numbers of T-cells and B-ells that can interact with 
the allergen. Many studies have indicated similar immunological mechanisms 
in ILIT as in other types of AIT, such as increase in IL-10 and allergen specific 
IgG4, induction of non-IgE producing plasmablasts, increase in Treg cells and 
a long-term T-cell unresponsiveness to allergen. One ILIT study measured the 
basophil reactivity but could not detect any change, despite improved symptoms 
after NPT and decreased SPT responses(53). It is possible that the mechanisms in 
ILIT are partly different from other AIT, since the first step of allergen exposure 
at the mucosa or close to the skin, is circumvented. 
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3 MATERIALS AND METHODS
3.1 Study design
The overall study design in paper I-III was a series of RDBPC trials where the 
study subjects were randomized to active ILIT or placebo ILIT in parallel groups. 
Paper IV was an open follow-up study 5-6 years after the RDBPC trial in paper 
II. (Fig 5-7). 
The patients were recruited at our study centers; Karolinska University Hospital, 
Skåne University hospital in Malmö and Lund, and Södra Älvsborg Hospital in 
Borås. In study I and II randomization was achieved with opaque envelopes. A 
nurse not connected to the study drew one envelope for each patient and prepared 
the medical product according to the study arm assignment in the envelope (active 
or placebo). In study III, a computer-generated randomization plan was used. 
3.1.1 Patients
General indications for conventional AIT were followed. Inclusion criteria were 
a history of moderate to severe AR according to ARIA guidelines at the pollen 
season, positive SPT and allergen specific IgE levels >0.3 kU/L (1). Exclusion 
criteria were severe atopic dermatitis, uncontrolled perennial asthma, symptomatic 
sensitization to house dust mite or furry animals with daily exposure, use of beta 
blockers or ACE inhibitors as antihypertensive medications, pregnancy or nurs-
ing, wish for pregnancy, known autoimmune or collagen disease, previous immu-
notherapy, obesity with BMI >30 due to potential difficulties visualizing lymph 
nodes with ultrasound, other significant diseases or withdrawn informed consent. 
Paper I: 30 patients aged 16 to 42 with mild asthma and AR towards birch or 
grass pollen. 
Paper II: 60 patients aged 18-55 with moderate to severe AR towards birch and 
grass pollen. 
Paper III: ILIT after SCIT- 10 000: 29 patients aged 18-55 that had recently 
completed SCIT for grass induced AR. ILIT de novo- 3000: 39 patients aged 
18-55 with moderate to severe AR towards grass without previous AIT treatment. 
Paper IV: 20 patients aged 18-55 with moderate to severe AR, previously treated 
with active birch and grass ILIT within a RDBPC trial 5-6 years previously. 14 
patients with moderate to severe AR towards birch and grass, without previous AIT. 
All studies were approved by the Ethical Review board in Stockholm and/or Lund 
and the Swedish Medical Products Agency, conducted according to good clinical 
practice guidelines and registered at ClinicalTrials.gov.
18
Paper I- ILIT young adults with mild asthma
Allergic rhino-
conjunctivitis
and mild asthma
SPT
Screening
Lung function Birch or 
grass
1000 U
Inj. 1
Week 0
1st
test, FENO
Methacholine BCT
Specific IgE 
Specific IgG4
NPT
ACT, AQLQ
pollen 
Placebo Placebo Placebo
season
Follow up 1
2nd
pollen 
Follow up 1 
Birch or 
grass
season
1000 U
Inj. 2
Birch or 
grass
Week 4
1000 U
Inj. 3
Week 8
Follow up 2
SPT
Lung function
Test, FENO 
Methacholine BCT
Specific IgE 
Specific IgG4
NPT
ACT, AQLQ
Recalled symptoms and 
medication scores
Birch or 
grass
Booster inj.
1000 U
Inj. 4
SPT
Lung function
test, FENO 
Methacholine BCT
Specific IgE 
Specific IgG4
NPT
ACT, AQLQ
Recalled symptoms and 
medication scores
Paper II- ILIT with two concomitant allergens
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Figure 5. Study outline in paper I and paper II. SPT= skin prick test, FENO= fraction of 
exhaled nitric oxide, BCT= bronchial challenge test, NPT= nasal provocation test, ACT= 
asthma control test, AQLQ= Asthma Quality of Life Questionnaire, RQLQ= Rhinitis 
Quality of Life Questionnaire. 
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Figure 6. Study outline in paper III. SCIT= subcutaneous immunotherapy, SPT= skin prick 
test, NPT= nasal provocation test, CSMS= combined symptoms and medication scores, 
RQLQ= Rhinitis Quality of Life Questionnaire. 
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Paper IV- ILIT 5-year follow-up
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Figure 7. Study outline in paper IV. NPT= nasal provocation test, CSMS= combined symp-
toms and medication scores, RQLQ= Rhinitis Quality of Life Questionnaire. 
3.1.2 Treatment protocols
3.1.2.1 Study I- ILIT in asthmatic young adults
30 patients received randomized treatment during 2012-2016 at Karolinska 
University Hospital. The primary outcome measure was reduction in NPT reactiv-
ity. Secondary outcomes were safety, AR and asthma symptoms and medication 
use during pollen season, allergen specific IgE, IgG and IgG4 levels, SPT, reac-
tion at a methacholine hyper responsiveness test, fraction of exhaled nitric oxide 
(FENO), asthma control test (ACT) scores and Asthma Quality of Life Questionnaire 
(AQLQ) scores. Active product was ALK Alutard® birch or grass with the dose 
1000 SQ-U. Three injections were given with 3-4 weeks interval. Placebo patients 
ended their participation after the first year. Patients that had received active treat-
ment returned the next year for an open pre-seasonal 1000 SQ-U injection 1-4 
months before the pollen season. In this open part of the study the same readout 
parameters were repeated.
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3.1.2.2 Study II- Intralymphatic immunotherapy with two concomitant allergens- 
a RDBPC trial
60 patients were recruited during 2012-2015 at Karolinska and Skåne University 
hospitals. Active treatment was ALK Alutard® birch and grass with the dose 1000 
SQ-U. Three injections were given with 3-4 weeks interval. Both birch- and grass 
allergens were given at the same visit, with 30 minutes of observation between the 
injections. The primary outcome measure was the symptoms at NPT with grass 
allergen. Secondary outcomes were safety, allergen specific IgE and IgG4, SPT, 
RQLQ, use of pharmacological treatment at pollen season, levels of T-cells and 
changes in T-cell activation in blood and lymph nodes.
3.1.2.3 Paper III- High dose grass pollen intralymphatic immunotherapy: two 
RDBPC trials question the benefit of dose increases    
In this paper, two trials investigated ILIT in up-dosing schedules, ILIT after SCIT- 
10 000 and ILIT de novo- 3000.
ILIT after SCIT- 1000 was a pilot study aimed at investigating the safety of 
a novel up-dosing regimen. The aim was to investigate if ILIT, with a higher 
allergen concentration than previously used, induced further amelioration of the 
allergy symptoms in patients already treated with SCIT. 29 patients were included 
during 2015-2016 in three participating study centers in Sweden. Inclusion cri-
teria were age 18-55 and a recent completion (within 20 months) of a full 3-year 
SCIT-program with amelioration of symptoms without reaching full symptom 
relief. The medical product and dose interval was the same as in previous studies 
but the doses were increased: Treatment 1: 1000 SQ-U. Treatment 2: 3000 SQ-U. 
Treatment 3: 5000 SQ-U + 5000 SQ-U with 60 minutes’ observation in between 
the injections. The primary outcome parameter was the CSMS during pollen sea-
son. Secondary outcome measures were safety, allergen specific IgE-and IgG4 
levels, SPT, NPT, and RQLQ. 
ILIT de novo- 3000 included 39 patients aged 18-55 with moderate to severe 
AR towards grass pollen that had not undergone previous AIT. This trial was per-
formed the year after ILIT after SCIT- 10 000, at Karolinska and Skåne University 
Hospitals. The regimen for treatment aimed at the same as in ILIT after SCIT- 
10 000. However, due to adverse reactions, the protocol was changed to: Treatment 
1: 1000 SQ-U. Treatment 2: 3000 SQ-U. Treatment 3: 3000 SQ-U. The outcome 
measures were the same as in ILIT after SCIT- 10 000 and, in addition, distribu-
tion and activation of T-cells and DCs in blood and lymph nodes. 
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3.1.2.4 Paper IV- A five-year open follow up of a randomized double-blind 
placebo-controlled trial of intralymphatic immunotherapy for birch and grass, 
reveals remaining beneficial effects
20 patients that had 5-6 years previously participated in the RDBPC trial described 
in paper II, treated with active birch and grass ILIT, were compared to 14 patients 
with moderate to severe AR towards birch and grass, without previous AIT. In the 
non-AIT treated control group, 8 patients had previously participated in the RDBPC 
trial. The primary outcome parameter was the birch and grass NPT. Secondary 
outcome measures were CSMS during pollen season, allergen specific IgE-and 
IgG4 levels, NPT, RQLQ, basophil activation test and distribution and activation 
of cells in lymph node and blood.
3.1.3 Intralymphatic injections
For the intralymphatic injections the lymph nodes in the groin were used. Here the 
lymph nodes are located shallow in the subcutaneous tissue. The injections were 
performed with aseptic technique and ultrasound guidance. To facilitate identifica-
tion of the lymph node the ultrasound picture was saved after injection. The same 
lymph node was then targeted with the same allergen at all injections. In study II, 
grass pollen was given in the left groin and birch pollen in the right groin. 
3.2 Evaluation of clinical improvement
3.2.1 Global assessment of symptom relief
Scoring on a visual analogue scale (VAS) is a fast and easy way to assess the overall 
symptomatic impact of AR for patients and researchers. Patients usually grade their 
symptoms on a continuous scale ranging from 0: “no symptoms” to 10: “highest 
level of symptoms”. This psychometric response scale has been used in several 
conditions. VAS is also validated for AR (82). The scale can be used in a compara-
tive fashion in order to evaluate a treatment. In that case the extreme limits at the 
scale are labelled with 0: “no relief” and 10: “complete relief” (83).  An advantage 
with the comparative scale is that the magnitude of the response does not depend 
on the severity of the initial condition. We used this type of comparative VAS in 
our studies. Disadvantages of the relief scale is that it creates the impression that 
all patients start at the same level of disease severity which may mask differences 
in outcome between patients. Also, patients need to recall their initial symptoms 
before they can assess their relief, which affects the reliability (83).
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3.2.2 NPT
To evaluate the rhinitis symptoms at allergen exposure, a nasal provocation (NPT) 
test can be conducted. It can be done by titrating increasing concentrations of 
allergen to determine the threshold that induces symptoms (84-86). It can also be 
performed by evaluating symptoms after only one dose (87, 88). To complement 
the subjective experience of responsiveness to allergen, objective measurements 
of the nasal air flow can be achieved with rhinomanometry or peak nasal inspira-
tory flow (PNIF) (89). 
An advantage of a provocation test is that the allergy symptoms are measured after 
the same allergen exposure for all patients and without the influence of symptom-
ameliorating pharmacotherapy. A weakness is that NPT does not fully represent the 
real-life seasonal pollen exposure (90, 91). NPT is recommended as a surrogate 
end point in proof-of-concept studies and novel AIT approaches (91). 
In our trials, the patients were challenged with 1000 SQ-U of ALK Aquagen® 
timothy or birch in each nostril. The patients scored rhinitis and conjunctivitis 
symptoms 0-3 at 0, 5, 15 and 30 minutes. 
3.2.3 Asthma
Asthma symptoms in study I were evaluated with the ACT before treatment and 
after the end of the pollen season (92). The score ranges 0-25 where 19 points or 
below indicates risk of uncontrolled asthma. A lung function test with measure-
ment of FEV1 and forced vital capacity was performed according to international 
standardization (93). Bronchial hyperresponsiveness to a methacholine challenge 
was assessed where the dose of methacholine that caused 20% reduction of FEV1 
(PD20) was calculated (94).
3.2.4 Quality of Life
Quality of life (QoL) is an important parameter when assessing disease burden of 
most conditions studied. There are several generic QoL questionnaires available 
as for example Medical Outcome Study 36-item short form (SF-36) (95). When 
studying changes within a medical condition a disease-specific questionnaire is 
often more sensitive (96). For allergy-related QoL, the Juniper Quality of Life 
Questionnaire (RQLQ) (97, 98) is widely used and recommended (91).
 In paper II-IV, the score was calculated as the average of 28 questions, each rang-
ing 0-6 (resulting in maximum RQLQ score 6 points) and the minimal clinically 
important improvement is 0.5 point (98). For asthma related QoL scoring in study 
I, the AQLQ score was used (92) with a similar 0.5 point level of minimal clini-
cally important difference.
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3.2.5 Daily combined symptoms and medication scores
A symptom- and medications diary is considered to be the most effective way to 
evaluate seasonal allergic symptoms (91), but is resource-demanding for study 
participants. There is a well-defined terminology for the symptoms scores (SS) in 
the eyes (ocular itching/grittiness/redness and ocular tearing) and for the symp-
toms in the nose (nasal itching, sneezing, rhinorrhoea and nasal obstruction). 
These symptoms are scored 0-3 every day during the pollen season. This allows 
tracking of the different symptoms and interpretation of the symptoms in relation 
to different pollen levels during the season. Daily scoring prevents recall bias. 
The consumption of rescue medications during pollen season is also recorded as medi-
cation score (MS). Numerous different ways to grade the use of different medications 
have been applied, for example use of antihistamine gives 1 point and the use of nasal 
steroid gives 2 points, etc. (91). The term rescue medication is often used for the symp-
tom ameliorating medication that is used by the patients at natural allergen exposure 
(e.g. pollen season) during the study period. This has nothing to do with medications 
used as treatment for allergic side reactions provoked by the immunotherapy treatment. 
The SS and MS can be used separately or, preferably, weighed together, since 
the use of pharmacological treatment has an impact on the symptoms. Recently, 
a European Academy of Allergy and Clinical Immunology (EAACI) task force 
recommended a simplified and standardized scoring system (91). In paper III we 
used this scoring system and all patients were instructed to use their medications 
stepwise, as needed, following the ARIA guidelines (99). The registrations were 
performed at baseline during the pollen season before the treatment and at the 
pollen season after the treatment.
3.2.6 Modified symptoms and medication scores
In paper I, modified SSs and MSs were assessed before treatment and after the 
first pollen season. The scores were calculated taking into account the frequency: 
daily (4 points); every second day (3 points); 1 to 3 days per week (2 points); 
occasionally (1 point); never (0 points), for the following symptoms: blocked 
nose, rhinorrhea, fatigue, sneezing, and asthma symptoms, and for the follow-
ing medications used: local and systemic antihistamines, nasal steroids, asthma 
medication, and eye drops. A maximum score of 20 points for symptoms and 16 
points for medication could be obtained.
In paper II, the use of antihistamine tablets, ocular antihistamines drops, intranasal 
steroid spray, corticosteroid tablets, β2 inhalation spray and corticosteroid inhalation 
spray were assessed after the first pollen season as reduced, unchanged or increased. 
In paper IV the same CSMS scores were used as in paper III, but repeated at six 
occasions during the birch and grass pollen season. 
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3.3 Immunological methods
3.3.1 Commercially available immunological tests
AR is an IgE-mediated disease. The diagnose relies on a typical history of rhino-
conjunctivitis symptoms at allergen exposure and either positive SPT or elevated 
serum-levels of allergen specific IgE antibodies. IgE can be measured with 
ImmunoCAP™ (Thermo Fisher Scientific, Uppsala, Sweden) at most hospital 
laboratories. The technology relies on high and specific binding capacity to a solid 
phase. The test is designed as a sandwich immunoassay. Allergen is covalently 
coupled to the solid phase, which then reacts with the specific IgE in the patient 
serum sample. Non-specific IgE is washed away and antibodies against IgE are 
added to form a complex. Unbound anti-IgE is washed away in a second step and 
the bound complex is incubated with a developing agent. The agent is fluorescent 
after the reaction has stopped and the intensity of the fluorescence correlates to 
the IgE level in the sample (100). 
Elevated serum-levels of allergen specific IgG4 antibodies are often associated 
with allergen exposure and/or tolerance induction and can be measured to moni-
tor the immune response and/or compliance in AIT (20). This test is also avail-
able as a fluoroenzyme immunoassay at the hospital laboratories, based on the 
ImmunoCAP™ technology.
3.3.2 SPT
Skin prick test (SPT) is a traditional method for demonstrating an allergic reac-
tion to a known allergen by provoking a small, immediate, allergic reaction in the 
skin. A panel of different allergen-containing drops is placed on the volar side of 
the forearm. A small lancet introduces the allergen shallowly into the skin (101). 
A positive control with histamine chloride in a concentration of 10 mg/ml and a 
negative control with saline buffer is used to confirm that the test is working. A 
wheal reaction of ≥3 mm after 15 minutes is usually considered positive. 
3.3.3 Flow cytometry
In paper II-IV, T-cell characteristics were determined with flow cytometry. In paper 
III, activation of DCs in blood and lymph nodes were also investigated. In paper 
IV we focused on T-cells and basophil activation. 
With ultrasound guidance, the lymph node was aseptically punctured with a 
22-gauge needle, aiming at the cortex/paracortex area. Lymph node aspirates were 
suspended in sterile PBS (Gibco™, Life Technologies, Uppsala, Sweden). When 
sampling blood, tubes containing a buffered trisodium citrate solution were used. 
Peripheral blood mononuclear cells (PBMC) were separated from whole blood 
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with ficoll density centrifugation (GE Healthcare, Buckinghamshire, UK). Flow 
cytometry was performed within 12 hours, with an LRS Fortessa (BD Biosciences) 
and the data were processed using FlowJo software© version 10.6.2 (Tree Star, 
Inc., Ashland, USA). 
Flow cytometry can measure several physical and chemical properties of single 
cells. It can be used in order to study the phenotype and understand the function of 
cell subsets. Suspended cells pass through a laser beam and individual cells scat-
ter the light differently (102). This enable measurements of the cell, regarding the 
cells’ size (Forward scatter, FSC) and granularity (Side scatter, SSC). The data are 
plotted in a two-dimensional dot-plot that can describe the relation between two 
different characterizations at a time. Specific areas of interest in the dot plot can 
be separated and monitored more closely, a process called “gating”. For example, 
the correlation between FSC-Height and FSC-Area allows gating of single cells 
and discard doublet cells (Fig. 8A). In the same way dead cells and debris that 
have low FSC-height can be gated away. The expression of intra- or extracellular 
proteins can be measured by adding a fluorochrome-conjugated antibody that 
binds to the antigen on the cells. The number of cells that are positively labelled 
can be measured, as well as the median fluorescence intensity (MFI). For exam-
ple, T-cells can be labelled and gated based on high expression of CD3 (Fig. 8B). 
These CD3+ T-cells can subsequently be divided into CD4+ and CD8+ T-cells per 
expression of the differentiation cell surface protein CD4 (Fig. 8C). 
      A.                                    B.                                       C. 
Figure 8. Flow cytometry. A. FSC-Height and FSC-Area. B. Expression of CD19 and 
CD3. C. Expression of CD4.
To characterize the cells in our studies, we used CD19 (B-cells) and CD3 (T-cells), 
CD4 (T helper cells) and CD8 (cytotoxic T-cells). To further determine the T-cells 
we used CCR7+CD45RA- (central memory T-cell), CCR7+CD45RA+ (naïve T-cell), 
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CCR7- (effector memory T-cell), CCR5 (Th1) and CRTH (Th2). We also used 
CD45+, SSC++ and CD11C+ (DCs), expression of CD80, CD86 and CD141 (acti-
vation of the DCs) and specific basophil markers mentioned below. To exclude 
monocytes in the analysis of blood we used CD14. For determination of positivity 
we used internal controls and fluorescence minus one controls.
3.3.3.1 Characterization of basophil cells
In paper IV, we investigated the activation of basophil granulocytes. These cells 
contain preformed granules, or vesicles, containing e g histamine. Positively and 
negatively bound molecules help forming the vesicles. When allergens crosslink 
IgE attached on the cell surface, the basophil cell degranulates by fusing the vesi-
cle membrane with the cell membrane. The expression of the vesicular membrane 
marker CD63 (103) and the positively charged marker for vesicular content avidin 
(104) were measured with flow cytometry. The blood was stimulated with 100 
SQ-U of grass allergen (0.2 mL of 500 SQ-U/mL ALK Aquagen®). Before flow 
cytometry analyses, the samples were incubated with antibodies enabling detec-
tion of basophil cells by their expression of HLA-DR and IgE. Other markers in 
the panel included CD45 (for setting the gate at the leucocyte detection area), 
CD63 and avidin (markers for activation), FcεR1 (IgE receptor) and membrane 
bound IgE (105). 
3.4 Statistical analyses
For the statistical analysis GraphPad Prism 6.01 software was used (San Diego, 
CA, USA). Statistical significance was set at p<0.05. NPT and other parameters 
measured repeatedly were analyzed with Friedmans test followed by Dunn’s 
multiple comparisons test when the data was not normally distributed or RM one-
way ANOVA if normally distributed. CSMS and other paired observations were 
analyzed with Wilcoxon match-pairs signed rank tests or paired t-test. VAS and 
other unpaired observations in the active versus the placebo or non AIT-treated 
group were analyzed with Mann-Whitney tests to compare ranks or un-paired 
t-test. Unpaired observations of DC activation were analyzed with Kruskal-Wallis 
test. The proportion of patients that changed medications were analyzed with Chi-
square tests. Power calculations were performed in all studies with a 2-sample 
t-test for the different primary outcome variables, and by comparing two paired 
means in paper IV. In paper III a generalized additive model (GAM) was used in 
a time-series analysis to evaluate the relative risk (RR) for allergy symptoms in 
relation to the pollen levels. These data were analyzed with the software R (Version 
R 3.3.3 GUI 1.69 Mavericks build, Vienna, Austria).
In the trials, all the patients that received one or more ILIT injections were 
included in the safety analysis. All the patients that completed the treatment and 
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follow up protocol were included in a modified intention-to treat (mITT) efficacy 
analysis. By this approach, patients that had missing data for any outcome were 
excluded from that particular analysis, but remained in the analysis of all the 
other parameters in order not to lose power (106). In addition, any patients that 
were found ineligible after randomization or did not complete the treatment were 
excluded from the analysis. The use of mITT analysis have been overrepresented 
at for-profit sponsorship trials and is described to confer a risk of arbitrary post-
randomization exclusions (107). However, the studies included in this thesis had 
no relevant conflicts of interests and all exclusions were justified and described 
in the CONSORT flow diagrams (108). 
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4 RESULTS
4.1 Paper I- Intralymphatic immunotherapy in pollen-
allergic young adults with rhinoconjunctivitis and 
mild asthma: A randomized trial
30 patients with mild asthma and moderate to severe AR induced by birch or grass 
pollen, were randomized double-blind to three intralymphatic injections of the 
corresponding allergen, or placebo. The doses were 1000 SQ-U at each injection, 
with one month-intervals. The active group returned for an open booster injec-
tion of 1000 SQ-U the second year. 14 active patients with median age 19.5 years 
and 12 placebo treated patients with median age 18 remained for analysis. In the 
active group, 11 patients had birch pollen induced AR and 3 patients had grass 
pollen triggered disease. In the placebo group 8 patients had birch pollen allergy 
and 4 patients grass pollen induced symptoms. 
Figure. 9. A. The MS were reduced in the active group but not in the placebo group. B. 
The SS improved in both the active and in the placebo group. A-B. (Active group n=11 
at 1st pollen season, n= 10 at 2nd pollen season. Placebo group n= 9) C. The NPT score 
did not change in the active (n=12), or in the placebo group (n=11). D. Allergen specific 
IgG4 antibodies (depending on the relevant allergen, birch or grass) were increased in the 
active (n=14 after 1st pollen season, n=13 after 2nd pollen season) but not in the placebo 
group (n=12). *p<0.05, **p<0.01. 
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Limited local reactions at the injection site were common. One patient had an 
urticarial rash in the forehead 20 minutes after the booster injection. This was 
successfully treated with corticosteroids and antihistamines and the patient could 
be discharged from the hospital after 4 hours of observation. One patient reported 
increased asthma symptoms during the day after the last injection. One patient 
got salivary glands swelling and cough 2 months after the booster injection and 
was diagnosed with sarcoidosis. Ultrasound examination of the lymph nodes that 
had received treatment did not reveal any swelling or granular appearance. The 
manifestations improved after systemic steroids and Methotrexate. No causal 
relationship with ILIT has been established.
The MS reflected the frequency of applications of the medicines and were reduced 
in the active group during the first pollen season after treatment. Placebo treatment 
did not change the need for rescue medications. After the open label booster ILIT 
injection year two, the MSs were further reduced (Fig. 9A). The recalled symptom 
scores (SS) were calculated considering the frequency and severity of the symptoms. 
SS improved in both the active and the placebo group after treatment. The score of the 
NPT was the sum of the symptom scores after the challenge, which did not change 
after treatment. The allergen specific IgG4 antibodies were increased 6-9 months after 
active ILIT, but returned to baseline 2 years after treatment, despite the booster injec-
tion. The placebo group did not change. (Fig. 9D.) Allergen specific IgG levels were 
also increased the year after active treatment but returned to baseline year two. There 
were no detectable changes in the allergen specific IgE levels. The clinical parameters 
improvement on VAS, ACT, AQLQ, response to bronchial methacholine challenge 
and measurements of FEV1 and FENO did not change, neither in comparisons within 
the groups nor in comparisons between the active and the placebo group. 
4.2 Paper II- Intralymphatic immunotherapy with 2 con-
comitant allergens, birch and grass: A randomized, 
double-blind, placebo-controlled trial
60 polysensitized patients,18-55 years old with birch and grass pollen induced 
moderate to severe AR were randomized double blind to three intralymphatic 
injections of birch and grass allergen, or three injections of placebo. The treat-
ments were given with one month-intervals and the doses were 1000 SQ-U at 
each injection. 27 placebo patients and 24 active patients remained for analysis.
The adverse events were mostly mild. In total 12 events of local reactions >5cm 
in size, were reported in the active group. One patient had a 5 cm local reaction 
combined with a genital herpes zoster reactivation and left the study after that event. 
One patient was treated with antihistamines and corticosteroid tablets. Two active 
patients had mild rhinoconjunctivitis symptoms the day after the first injection. 
No other relevant systemic reactions were reported and no Adrenaline was used.
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The grass allergen reactivity following NPT was reduced by 28% in the active 
group 6-9 months after the treatment, compared to the baseline. The placebo group 
exhibited no reduction (Fig. 10).
The RQLQ scores during the birch pollen season showed a trend for improvement 
in the active group with an average 1.0-point reduction of the symptom scores in 
the active group compared to placebo (Fig.10). Some domains displayed significant 
differences; mean nasal symptom scores were 1.1 points lower in the active group 
than in the placebo group, non-nose/eye symptom scores were 1.0 points lower 
and emotional symptoms scores were 0.8 points lower than in the placebo group.
Figure 10. A-B. The grass allergen NPT showed 28% reduced reactivity in the active group 
(n= 23) 6-9 months after treatment while the placebo group did not change (n=26). C. The 
total RQLQ scores reported were lower in the active group (n=20) compared to the pla-
cebo group (n=15) at the birch and grass pollen season after treatment, but the difference 
did not reach significance. D. More patients in the active group (n=24) had a reduced or 
unchanged use of antihistamines and/or nasal steroids than in the placebo group (n=27). 
*p<0.05. A-C Horizontal lines at mean and SD.
The medication use was more reduced in the active group than in the placebo group 
after treatment. After the pollen season, 92% of the active patients reported less or 
unchanged use of antihistamine tablets and/or nasal steroid, whereas 63 % of the patients 
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in the placebo group reported unchanged or reduced use. Treatment effects measured 
as improvement on VAS, scored after the pollen season, did not show any changes.
The grass specific IgG4 as well as IgE antibodies in sera were increased in the 
active group after ILIT, whereas the birch specific IgG4 and IgE levels remained 
unchanged (Fig. 12). Flow cytometry analysis of lymph node material revealed 
an increased amount of CD4+ and CD8+ memory T-cells after ILIT. For both cell 
populations, the effector memory T-cells increased more than the central memory 
T-cells. In blood, the Th1 cells (determined as CCR5+ CD4+ T-cells) and Tregs 
(determined as CD25++ CD4+ EM T-cells) increased (Fig. 11).
Figure 11. A. The amount of CD4+ memory T-cells increased in the ILIT-treated lymph 
nodes (n=7) but remained unchanged after placebo treatment (n= 8). B. The effector 
memory T-cells increased more than the central memory T-cells, in the active group (n=7). 
There were no changes of the proportions in the placebo treated lymph nodes (n=6) C. 
The Th1 cells increased in blood after active ILIT (n=11) but not after placebo (n=12). 
D. The Treg cells increased in blood after active treatment (n=10) but were unchanged 
in the placebo group (n=10). *p<0.05. ***p<0.001. 
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Figure 12. A. The birch specific IgG4 levels did not change in the active or in the pla-
cebo group. B. The timothy specific IgG4 antibodies increased after active ILIT (n=24) 
but not after placebo (n=25). ***p<0.001.
4.3 Paper III- High dose grass pollen intralymphatic 
immunotherapy: two RDBPC trials question the 
benefit of dose increases    
In these studies, ILIT with up-dosing protocols was evaluated in two RDBPC tri-
als; “ILIT after SCIT- 10 000” and “ILIT de novo-3000”.
In ILIT after SCIT- 10 000, 29 patients that had recently ended SCIT treatment for 
grass induced AR were included. The patients were randomized double-blind to 
three intralymphatic injections of placebo or grass allergen extract in increasing 
doses; 1000- 3000- 10 000 SQ-U, with injections every 4-6 weeks. All the patients 
that started the treatment completed the protocol, without any moderate or severe 
adverse events, and could be included in the analysis. 
The primary outcome measure was the daily CSMS at the pollen season, expressed 
as AUC for the entire study period. The CSMS was reduced by 31% in the active 
group at the pollen season after treatment compared to the year before treatment. 
The CSMS in the placebo group did not change (Fig. 13). The between groups 
analysis of CSMS in the active versus the placebo group did not reveal any dif-
ference, although a comparison of the change in CSMS from the baseline season 
to the post treatment season, in the active versus placebo group, showed a trend 
for more improved scores in the active group (p=0.059, unpaired t-test). Among 
the secondary outcomes, the MS improved the year after treatment in the active 
group but not in the placebo group. Grass-specific IgG4 antibodies were increased 
in the active group after treatment, whereas the placebo group displayed a steady 
decline in specific IgG4 after the withdrawal of SCIT (Fig. 14).
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Figure 13. A. In ILIT after SCIT, the CSMS was improved in the active group (n=13) after 
treatment. The placebo group (n=11) did not show any change. B. In ILIT de novo- 3000, 
the placebo (n=18) and the active group (n=15) scored an equal improvement in CSMS 
after treatment. **p<0.01.
In ILIT de novo- 3000, 39 patients with moderate to severe AR due to grass pol-
len allergy were recruited. These patients had not undergone AIT previously. The 
same dose-escalation protocol as in ILIT after SCIT- 10 000 was attempted but 
could not be followed. The first two patients that received the 5000 SQ-U dose 
had anaphylactic reactions. The adverse events were treated successfully and the 
patients could be discharged from the hospital the same day. The up-dosing was 
interrupted for the remaining patients. They instead received a third 3000 SQ-U 
dose resulting in the modified protocol of 1000-3000-3000 SQ-U. 
19 placebo treated patients could be compared to 16 actively treated patients in the 
efficacy analysis. At the time for the evaluation, one year after the vaccination, the 
pollen levels were markedly lower than during the baseline year. This was reflected 
as improved CSMS, SS and MS scores in both the active and the placebo group (Fig. 
13). However, at the peak pollen season, the placebo group but not the active group 
showed improved scores. Similarly, the quality of life at the peak pollen season 
was improved in the placebo group but not the active group. Grass-specific IgG4 
levels, but also grass specific IgE levels, were increased 4 weeks after treatment 
(Fig. 14). Flow cytometry analysis on lymph node aspirations revealed increased 
expression of activation markers on DCs (Fig. 15). Increased expression of CD86 
was positively correlated to a favorable treatment outcome expressed on VAS. The 
proportion of memory cells in the lymph nodes was unchanged and the amount 
of Th1 cells and T reg cells in blood was not increased.
35
Figure 14. A. Grass specific IgG4. In ILIT after SCIT the grass specific IgG4 levels 
decreased in the placebo group during the course of the study (n=11), while the active group 
had a boost in the specific IgG4 levels after treatment (n=13). B. In ILIT de novo- 3000, 
the active group showed a moderate increase in grass specific IgG4- levels (n=16). The 
placebo group did not change (n=19). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
Figure 15. Activation of DCs from the lymph nodes in ILIT de novo-3000. DCs dis-
played an increased expression of A. CD86 and B. CD141 in the active group (n=9) but 
not in the placebo group (n=11). *p<0.05. The outcome after treatment was compared to 
pooled data from the active and the placebo patients (n=11) before treatment. 
36
4.4 Paper IV- A five-year open follow up of a randomized 
double-blind placebo-controlled trial of intralym-
phatic immunotherapy for birch and grass, reveals 
remaining beneficial effects
20 out of 25 eligible patients from the active arm in the previous RDBPC-trial 
(paragraph 4.2 above) could be enrolled in an open long-term follow-up study. 
In the placebo group, only 8 out of 28 patients could be included; 8 patients had 
undergone AIT, 5 patients had moved away and the remaining did not give consent. 
6 new patients with birch and grass pollen induced AR were included in the study 
and analyzed together with the placebo patients, as a non AIT-treated control group. 
The primary outcome measure was reactivity following grass allergen NPT. The 
analysis could not detect any remaining effect on NPT in the active group, com-
pared to baseline before treatment (Fig. 16A). When comparing grass NPT in the 
previous active ILIT group with the non-AIT treated control group, there were 
lower scores in the ILIT-treated group (Fig. 16B). The birch NPT did not reveal 
any differences between the groups. The modified seasonal CSMSs were lower 
in the active ILIT-group compared to the non AIT-treated group, at the birch and 
the grass pollen seasons (Fig. 16). When examining the medication use separately, 
there were lower MSs at the birch and grass pollen seasons in the active group. 
The SSs did not differ between the groups.
Figure 16. A. The reactivity at grass NPT was the same 5-6 years after ILIT compared to 
baseline in the placebo (n=6) and the active (n=19) group. B. The NPT scores 5-6 years 
after treatment were lower in the ILIT-treated group (n=19) compared to the non AIT-treated 
control group (n=12). C. The CSMSs were lower in the ILIT-treated group (n=18) compared 
to in the non AIT-treated group (n=9-11). *p<0.05. B-C. Horizontal lines at median and 
interquartile ranges. Dots represent patients from the previous RDBPC-study. Triangles 
represent new AR-patients without previous AIT or participation in the RDBPC-study.
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The active group, that had an increase in grass specific IgE directly after ILIT-
treatment, had 5-6 years later lower specific IgE levels compared to baseline. At 
the time of the follow up a detectable increase in the levels of grass specific IgG4 
antibodies could still be seen (Fig. 17). Birch specific IgE and IgG4 antibodies were 
unchanged compared to levels seen before treatment. Flow cytometry revealed 
higher amounts of B-cells in the lymph nodes of previously ILIT-treated patients 
compared to the control group. The total amount of T-cells in the lymph nodes were 
the same but the ILIT treated group showed a larger proportion of memory cells 
than the non-AIT-treated group.The previously seen differences in the levels of 
Th1 cells and Treg cells in blood in the ILIT treated group could not be reproduced.
Figure 17. A. The grass specific IgE levels had decreased 5-6 years after ILIT (n=20). 
B. The grass specific IgG4 levels were slightly increased 5-6 years after ILIT (n=20). 
*p<0.05, **p<0.01. 
Figure 18. Patients treated with active ILIT displayed an increased fraction of CD4 memory 
T-cells. *P<0.05, Horizontal lines represent the mean value and SD. Triangles represent 
new AR-patients without previous AIT or participation in the RDBPC-study.
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5 DISCUSSION
5.1 Safety
One of the main advantages of ILIT is the possibility to use lower allergen doses 
than in other forms of AIT. The allergen is administered directly into the lymph 
nodes. They contain a high abundance of T-cells and B-cells, which hypotheti-
cally confers a high chance of allergen specific immune reactions even with low 
concentrations of the allergen. In addition, the lymph nodes contain relatively 
few mast cells and basophils, reducing the risk of immediate side effects further. 
5.1.1 Injection technique
The goal is to deliver all the allergen into the lymph node guided by ultrasound, 
but not all injections are successful. Occasionally, some of the allergen is deposited 
just outside the node. This can be related to leakage from the node or inadequate 
placement of the needle. The former could, to some extent, be prevented by a slow 
injection. Sometimes the lymph node is surrounded by a rather tough capsule that 
can be difficult to penetrate and the allergen is deposited in the immediate vicinity. 
Injection of allergen outside of the lymph node most likely increases the risk for 
local adverse reactions and may, in the extreme situation, if erroneously placed 
into the femoral vein or artery, be life threatening. In doubt of the needle position 
it is advisable to aspirate before the injection to rule out intravascular position. 
Pre-requisites for an optimal ILIT injection include a comfortable patient that can 
refrain from moving during the procedure, good ultrasound visualization, a slow 
injection with or without preceding aspiration.
5.1.2 Allergic adverse events
5.1.2.1 Dosing schedules up to 1000 SQ-U
We used the same doses as in previous ILIT studies, three injections of 1000 
SQ-U ALK Alutard® with one-month intervals (paper I-II) (52-54, 59, 61). No 
serious adverse reactions were experienced. Our studies confirm the notion that 
this ILIT schedule is safe, also when used for two allergens, birch and grass, given 
concomitantly, with 30 minutes in between. It is important to notice that uncom-
mon reactions might occur and that it can take several years of use before they 
can be revealed. There will probably never be an AIT treatment involving crude 
allergens, as Alutard®, without a risk for side effects. Hence, the same rigorous 
routines for monitoring patients after the injections as in SCIT should therefore 
always be practiced also in ILIT.
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In paper I, the participants had to have a confirmed history of mild asthma in 
addition to AR. There were no acute obstructive reactions in conjunction with the 
injections, but one patient reported asthma symptoms during the day after one of 
the injections. All patients were well controlled with a median FEV1 of 97.5%, a 
median FENO  of 20.5 and median ACT of 21 at enrollment. It is possible that the 
safety profile is not as good among patients with more severe asthma, as in the 
present study. In paper III, ILIT de novo- 3000, perennial asthma constituted an 
exclusion criterion, whereas seasonal asthma was permitted. Two patients reported 
heavy breathing as a late reaction after the first 3000 SQ-U dose. Both patients had 
seasonal asthma but denied persistent symptoms and had a normal lung function 
test with FEV1 >80%. One of the patients was withdrawn from the study after 
that reaction. The other patient continued the up-dosing to 5000 SQ-U at which 
he experienced an anaphylactic reaction. Hence, special caution should be taken 
with asthma in ILIT (11). 
In paper II, polysensitized patients were treated with two allergens, birch and grass. 
No serious systemic adverse events were recorded. Among 30 active patients there 
were 12 local reactions at the injection site (40%). This is low compared to local 
side effects reported in SCIT. According to a systematic review in 2007, pooling 
results from 30 RDBPC trials, 834 events of local reactions occurred among 907 
active patients (92%) (109). In a more recent review from 2017, 26-86% of all 
patients that received SCIT experienced large (> 2.5 cm) local reactions (110). 
Hence, ILIT with injections of one or two allergens in the dose 1000 SQ-U at 
one-month-intervals seems to induce fewer local and systemic adverse reactions 
than regular SCIT.
5.1.2.2 Dosing schedules up to 10 000 SQ-U
The tolerance inducing effect of AIT is, according to the prevailing paradigm, 
dependent on a high dose of allergen to mount a tolerogenic immune response 
(111). Patterson et al. have performed “high” up-dosing of ILIT in seven patients 
without adverse reactions (112). That study used Center-AL®, which is an alu-
minum adsorbed allergen extract available in the USA. The up-dosing reached 250 
PNU (protein nitrogen units), which corresponds to the 5th dose of an 11 weeks 
up-dosing schedule for SCIT with Center-AL®. We used Alutard® to gain a cor-
responding dose increase in our ILIT studies. The protocol chosen of 1000-3000-
10 000 SQ-U was estimated to be in the same range as the Center-AL® to 250 
PNU, even though a direct comparison of these extracts is hard to make.
Dose escalation to 10 000 SQ-U was safe, probably due to the tolerance induced 
after the recent SCIT treatment (Paper III). These patients had completed three 
years of SCIT including both up-dosing and maintenance. Not more than 20 months 
was allowed between the last maintenance dose of SCIT and the first ILIT dose. 
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An extended time frame could perhaps have been accepted, since it is widely 
acknowledged that the reduction of airway symptoms upon SCIT is much longer 
than three years and symptom reduction is believed to reflect tolerance induction 
(13). Accordingly, a too long period between SCIT and ILIT might be risky, since 
the protective effect after SCIT declines with time. 
An up-dosing of grass allergen from 1000 to 3000 SQ-U among previously unvac-
cinated patients appeared to be safe (ILIT novo- 3000). In contrast, further dose 
escalation to 5000 SQ-U, triggered anaphylactic reactions in two out of two patients. 
Since the state of readiness was high these complications could be handled without 
delay and the patients released from the hospital within 4-6 hours. Nevertheless, 
we found these reactions to be a bit surprising since the dose escalation from 3000 
to 5000 SQ-U corresponds to half a logarithmic step, a step size commonly used 
during the traditional up-dosing in SCIT. 
Various explanations for these anaphylactic reactions could be contemplated. First, 
the extract used at the 5000 SQ-U doses, was prepared by diluting the allergen to 
the final concentration 50 000 SQ-U/mL. An error in the mixture might have hap-
pened, but the procedure was carried out with meticulous measurements and an 
erroneous allergen content in the final vial is not likely. Further, the two patients 
that encountered the anaphylactic reactions might have been hypersensitive to the 
allergen used. One of the patients had reported heavy breathing and palpitations 
4-8 hours after the injection already at 3000 SQ-U, which was noted but assessed 
as unspecific. This might represent a late systemic reaction signaling a risk for 
hypersensitivity reactions in this particular patient, if interpreted with caution. At the 
same time, the other patient did not experience any side effects after the preceding 
injection and yet had an anaphylactic reaction at injection number three. A third 
possibility is that the allergen after the injection was drained fast to the hilus of 
the lymph node and further to the venous system via the thoracic duct, causing the 
rapid systemic reaction. If so, this might be prevented by an even slower injection. 
It is interesting to notice that the two patients that received 5000 SQ-U did not 
display any signs of symptom improvement during the pollen season, nor did the 
other patients in the active group that were up-dosed to 3000 SQ-U. It is there-
fore tempting to conclude that higher doses than 1000 SQ-U in ILIT, with dose 
intervals of 1 month, fail to induce tolerance, resulting in a lack of clinical effect 
and a severe risk for anaphylaxis.
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5.1.3 Non-allergic adverse reactions
5.1.3.1 Infections 
One placebo patient in study II had clinical signs of epididymitis 1 week after the 
last injections. Hypothetically, a retrograde infection from the inguinal lymph node 
could be the cause of this but seems unlikely considering the drainage of lymph 
fluid. One placebo patient in study III developed fever and swelling in the groin 
after the second injection. This resolved spontaneously within 24 hours, before it 
was reported to the study staff. It might represent a local injection-related infection, 
but the etiology is hard to determine in retrospect. Infections due to the injections 
are extremely rare in SCIT (21). Injections in the inguinal region are possibly more 
prone to be contaminated. Aseptic technique should be used. 
5.1.3.2 Autoimmune diseases
One patient in study I was diagnosed with sarcoidosis after the booster injec-
tion. Investigations including analysis of blood samples and bronchoalveolar 
lavage could neither confirm nor rule out a connection to ILIT. Sarcoidosis is an 
inflammatory disease of unknown etiology, with overlapping pathogenesis with 
autoimmune disorders, including clusters of activated T-cells. Sarcoidosis-like 
manifestations have been described in conjunction to other immune modulating 
drugs (113). Sarcoidosis is a relative contraindication for SCIT since the Alum 
adjuvant have been suspected to cause nodular granuloma formation at the injec-
tion site in sarcoidosis patients (114). To the present knowledge, AIT is not a risk 
factor for sarcoidosis or other autoimmune disease (114), although one case report 
has suggested that the responses following AIT might be one of several predis-
posing triggers (115). The fact that the present patient did not suffer from lymph 
node engagement in the inguinal region, might speak against a causal relationship. 
5.2  Clinical effect
5.2.1 Three ILIT doses of 1000 SQ-U (paper I and II)
5.2.1.1 Medication use
The outcome of three 1000 SQ-U doses of ILIT indicated improvement of AR 
demonstrated as less need for symptom relieving medication during the subsequent 
pollen season. The patients evaluated their use of medication after each pollen 
season using a modified scoring system (paper I), and by categorizing the need 
for symptom relieving medication as reduced, unchanged or increased (paper II). 
Both studies found a reduction of these scores. This finding is in line with the 
first ILIT-study from Senti et al. that used grass allergen in the same doses (52). 
They reported that the number of antihistamine tablets used during the grass pol-
len season was lower after ILIT. 
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The scores in study I represent pooled results from birch and grass ILIT, which 
is a limitation. However, most of the patients received birch ILIT which implies 
that also birch allergen ILIT is effective. Study II included an open booster injec-
tion at the consecutive year in the active group which reduced the medication use 
further during year two, but these findings are preliminary and in the absence of 
a control group. 
5.2.1.2 NPT
The primary outcome in both studies was the reactivity as measured by NPT. In 
study II, a reduction of the rhinoconjunctivitis symptoms was seen in the active 
group. A 28% improvement In NPT reactivity cannot be directly translated to a 
corresponding level of protection at seasonal exposure, but it incontrovertibly 
argues for a positive effect of ILIT. NPT with birch allergen was not performed 
due to logistical reasons and this is a limitation in the study. One drawback of NPT 
is the well described high variability of the test (86), which confers the need for a 
large sample size to detect changes. This might explain why it was not possible to 
detect any reduction in NPT symptoms in study I, that had a smaller sample size. 
Improvement of NPT scores have also been demonstrated in other ILIT trials. The 
first ILIT trial of Senti et al. (52), that also used grass pollen allergen, demonstrated 
increased thresholds at NPT, as did a subsequent smaller open ILIT trial of grass 
allergen (53). Other ILIT trials include a recently published RDBPC study of 
Japanese cedar pollinosis. The active cedar group showed less symptoms during 
three years of repeated NPT:s at follow up visits, in comparison to baseline. The 
placebo group did not improve. However, the placebo group was smaller than the 
active group since a 1:2 allocation ratio was used. This undermines the possibil-
ity to compare the changes within each group. Another RDBPC trial that used a 
modified cat epitope allergen (58) revealed increased tolerance to nasal allergen 
after active ILIT compared to placebo. 
In summary, several ILIT trials have shown reduced NPT reactivity with various 
allergens. The study in paper II is the first RDBPC trial that demonstrates improve-
ment at grass allergen challenge after ILIT.
5.2.1.3 Seasonal symptom improvement
In study I, we studied if ILIT also affects asthma favorably. The asthma param-
eters turned out to be unchanged after treatment. This is most likely explained 
by the fact that all patients were on optimal asthma treatment at enrollment with 
well controlled disease. No attempt to withdraw medications was performed so 
there was little room for improvement. In study II, the active patients reported a 
reduction in the use of β2-agonist inhalations during the birch pollen season after 
treatment, a finding that might suggest a protective effect on bronchial obstruction. 
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None of the studies with ILIT 1000 SQ-U could verify an improvement on seasonal 
AR symptoms that exceeded the treatment effect in the placebo group. In study I, 
the recalled SS was reduced in both the active and the placebo group. In study II, 
the active and the placebo group estimated an equal treatment effect on VAS. In 
other respects, the intra-seasonal scoring of AR related QoL in study II showed a 
trend towards a clinically relevant improvement during the birch pollen season. 
In fact, there was a significant improvement in the active group compared to the 
placebo group in some domains, e g nasal symptoms. 
Generally, the evaluation of symptoms scored after the pollen season is hampered 
by the risk of memory bias and can therefore only be a rough estimation of the 
outcome. We have previously, in a smaller ILIT study from 2013 (59) found an 
improvement on VAS. This disparity might in part be related to differences between 
the recruited populations. The 2013 study enrolled patients from the waiting list 
for SCIT with severe AR. The participants in paper I and II were recruited from 
the pediatric asthma clinic and from newspaper advertising, possibly with a lower 
grade of disease severity. Evaluation of the AIT outcome in highly symptomatic 
patients is more likely to demonstrate a positive effect, than among patients with 
less pronounced symptoms (116).
5.2.1.4 Lessons learned of use for our subsequent ILIT studies
The reduction of NPT induced rhinoconjunctivitis symptoms (paper II) and the 
diminished consumption of symptom relieving medication (paper I and II), provided 
evidence for a good ILIT efficacy with three doses of 1000 SQ-U. The RDBPC 
study design is a strength in our studies and the relatively small sample sizes and 
blunt evaluation tools are weaknesses. The latter might be one explanation to why 
we could not convincingly prove an effect on the seasonal symptoms. As stated 
before, the effect of AIT is generally believed to increase if higher doses of allergen 
can be given. Therefore, the next ILIT trials described in paper III were designed 
as an up-dosing study. We also sharpened the inclusion criteria regarding disease 
severity and switched the primary outcome measure to the CSMS. 
5.2.2 ILIT in doses higher than 1000 SQ-U (paper III)
The two trials in paper III, “ILIT after SCIT- 10 000” and “ILIT de novo- 3000” 
investigated a dose escalation protocol that aimed at enhancing the clinical effect 
of ILIT. 
5.2.2.1 ILIT after SCIT- 10 000
In ILIT after SCIT- 10 000, patients with grass pollen induced AR that had recently 
completed a SCIT treatment without full symptom control, received ILIT in doses 
1000- 3000- 10 000 SQ-U. The year after treatment, the CSMS was reduced by 
31%, the MS was reduced by 52% but the symptom score SS was unchanged. 
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The World Allergy Organization recommends that the primary outcome measure 
in AIT trials should compare the CSMS in the active versus the placebo group 
and the relative difference should exceed a 20% improvement(117). Neither the 
between group comparisons of CSMS in the active vs the placebo group, nor the 
change in CSMS, reached statistical significance in ILIT after SCIT- 10 000 and 
this is a weakness. Comparing two seasons with different pollen burden may intro-
duce a bias due to the variability in allergen exposure. In the present study, the 
pollen counts were indeed 17-21% lower during the posttreatment year compared 
to baseline. Despite this, the placebo group did not improve the CSMS, which 
might illustrate a gradual decline of the symptom control gained at previous SCIT 
and advocates a true improvement in the active group.
Two previous studies have monitored the efficacy of AIT for grass pollen induced 
AR by comparing two consecutive grass pollen seasons (118, 119). The first study 
presented improvement on VAS as well as intra-seasonal symptoms and medica-
tion use after SLIT. The second study demonstrated a significant difference in 
the change of AUC of CSMS comparing 132 active patients versus 49 placebo 
patients, in favor of active grass SLIT. The secondary outcomes SS and MS were 
also improved. These findings derived from a 39% absolute reduction of CSMS 
in the active group to 37% reduction of SS and 41 % reduction of MS. 
The calculation of medication weighted symptoms have varied between the pre-
viously formed AIT- trials (120) which make direct comparisons of the improve-
ment difficult. Systematic reviews estimate that the treatment effect in different 
CSMS, relative to placebo, in recent and well powered SCIT and SLIT trials 
range from 26 to 36 % (24). A systematic review of the treatment effect of grass 
SLIT treatments determined the reduction in MS, relative to placebo, to 27-38% 
(121). Moreover, when comparing SLIT to symptom relieving pharmacotherapy 
treatment alone, the improvement in total nasal symptom scores (comparable to 
SS) relative to placebo was 16% for SLIT, 9% for Desloratadine (antihistamine 
tablet) and 22% for intranasal steroid spray. Lastly, a recent SLIT trial using the 
exact same CSMS scoring system as we did in ILIT after SCIT-10 000, exhibited 
a 32% reduction of CSMS in relation to placebo (122). 
Secondary outcome measures did not support the findings in ILIT after SCIT-10 
000, drawbacks of each method have been discussed earlier. To note, the patients 
in ILIT after SCIT- 10 000 had lower NPT scores at baseline compared to untreated 
patients. The allergen dose used at the provocation might be too low among SCIT-
treated patients to elicit a reaction that can be improved after ILIT.
When comparing these previous AIT-trials to ILIT after SCIT- 10 000, the result 
with 31% improvement of CSMS within the active group is probably somewhat 
below the effect of established AIT-forms but might exceed the minimal clinically 
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important difference of 20% in relation to placebo. The absolute MS reduction 
of 51% seems to be in the same range as other AIT-treatments that have 27-38% 
reductions relative to placebo, but since the patients in our study had been SCIT-
treated the different study populations might play a role, as well as limitations in 
the statistical methods with a small study sample. Nevertheless, aiming at finding 
new cost-effective treatment forms for AR, these results are encouraging.
5.2.2.2 ILIT de novo- 3000
The key question of the twin studies in paper III was to investigate whether an up-
dosing of ILIT could further improve the therapeutic effect in previously unvac-
cinated patients, at least in doses up to 3000 SQ-U. Disappointingly, the results 
did not support any improvement. The active group did not exhibit improvements 
in any of the parameters including the daily scoring, RQLQ, VAS and NPT. If 
anything, the non-treated group seemed to enjoy a placebo effect with improved 
CSMS and RQLQ during the heights of the pollen season, which the actively 
treated patients did not. This might even suggest an aggravation of the allergic 
symptoms among actively treated patients. Even though the sample size of this 
study was limited, a larger treatment effect could not have remained undetected.
5.2.3 Long term effect of ILIT in 1000 SQ-U (paper IV)
Study IV was an open follow up study 5-6 years after the RDBPC ILIT trial for 
birch and grass induced AR (paper II). The follow-up could not verify any long-
term effect on sensitivity at NPT, which was the pre-specified primary outcome 
measure. However, the comparisons of CSMS and NPT revealed that the scores 
were lower in the ILIT treated group than in the control group consisting of previ-
ous placebo-ILIT treated patients and newly recruited AR-patients. This suggests 
a long-term protective effect of ILIT. 
Limitations of this study include the open study design. However, breaking the 
study codes after the first season in the RDBPC trial was the only option in order 
to recruit participants. Secondly, all patients in the control group had not been 
previous participants in the RDBPC trial. Thus, they were not allocated randomly 
to the control group. Differences between the previously ILIT treated group and 
non-AIT treated control group might therefore be attributed to other factors than 
the treatment. The new patients in the control group might have had a more severe 
AR compared to baseline values of the active group. Nevertheless, examining the 
CSMS and NPT scores visually revealed that the control patients are not outli-
ers in comparison to the previously placebo treated ILIT patients (Fig. 16 B-C).
At the follow up visits, many patients stated that the effect of ILIT had lasted for 
3 years. This is in line with the first ILIT trial 2008 and a recent RDBPC trial 
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of Japanese cedar pollinosis, that measured improvements during 2-3 years (52, 
123). SCIT and SLIT usually require 3 years of treatment to display long-term 
effects at least two years after completed treatment. Two years of treatment is often 
insufficient to reach a sustained effect after the treatment withdrawal and 1 year 
of treatment is sometimes not enough to achieve short term improvement at the 
first season (12). In the light of this, the now often standardized ILIT protocol of 
three visits during 8 weeks might be supplemented by yearly pre-seasonal booster 
injections during e g three years, harmonizing the total treatment period of ILIT 
with other forms of AIT. 
5.2.4 Summary of treatment effect
In summary, our presented data strongly support a good clinical effect of ILIT 
given as 1000-SQ-U during 8 weeks. Further, we found no evidence for that a 
further increase of the dose should be beneficial. Rather the contrary, higher doses 
might be decremental with loss of clinical effect and increased risk for severe side 
effects. In the special case when a higher dose, 10 000 SQ-U, is given to an already 
SCIT treated population therapeutic gains might be reached without compromising 
the safety.  When considering ILIT as a future alternative in AIT it is important to 
acknowledge that many of the early SLIT studies failed to verify a positive effect, 
hampered by unknown factors such as optimal dose, type of preparation, duration 
of treatment and mode of intake (124). It seems as ILIT presently might be in the 
same developmental position as SLIT was 10-20 years ago. 
5.3 Mechanisms in ILIT
5.3.1 Allergen specific IgE and IgG4
We observed increases in the allergen specific IgE and IgG4 levels shortly after 
administration of active treatment (paper I-III). The follow up 5-6 years after 
1000-SQ-U ILIT, presented in paper IV, revealed that the timothy specific IgE 
had decreased to levels below the baseline values. Similarly, the levels of timothy 
specific IgG4 had returned towards baseline but were still slightly elevated com-
pared to before treatment. This suggests a favorable induction of IgG4 producing 
B-cells with a short onset and long-term duration. Other ILIT studies have dem-
onstrated increased IgG4 levels specific for cat dander, house dust mite and grass 
(56-58, 61) even though the grass-ILIT trial of Witten et al. (61) did not prove a 
clinical improvement. These serologic findings are in line with findings in con-
ventional AIT, with an increase in allergen specific “blocking” IgG4 antibodies 
upon treatment. The transient increase in the timothy specific IgE levels, followed 
by a gradual decline, also mimics the pattern induced by other forms of AIT (20, 
125, 126). One ILIT-study could not detect any boost in allergen specific IgG4 
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but found an increase in plasma cells producing non-IgE antibodies, suggestive 
of a shift in antibody production (53).
The changes in timothy specific IgE and IgG4 responses in paper II and IV were 
not mirrored by changes in antibodies specific for birch. This might be an effect 
of differences in the relative allergen content between the two allergen extracts 
used (127). This discrepancy might be neglectable in SCIT but have more impact 
in ILIT where the total doses used are far lower. However, the pooled birch and 
grass allergen specific IgG4 results in paper I did show an increase, supporting 
evidence of a birch specific IgG4 class switch.
The timothy specific IgG4 levels in ILIT after SCIT-10 000 showed a larger increase, 
starting at a higher baseline level, than in the 1000 SQ-U studies. This difference 
in baseline levels can be attributed to an expanded memory B-cell population with 
inducible IgG4 production after the previous SCIT. ILIT de novo- 3000 boosted 
the timothy specific IgG4 levels, to the same extent as in paper II, but without 
accompanying symptom relief. So, it is tempting to conclude that complex mecha-
nisms involved in successful AIT involves other or additional cellular changes, 
that might not have been achieved when using higher doses of ILIT.
5.3.2 T-cells
In lymph nodes we found an induction of effector memory T-cells and an increase 
of Treg cells and Th1 cells in blood (paper II). These findings were not seen at the 
follow-up 5-6 years after treatment (paper IV). Instead, the cells from the lymph 
nodes contained a higher proportion of total memory cells than the untreated group, 
with a tendency of more central memory T-cells in the active group compared to 
the placebo group.  
The expansion of IgG4 instead of IgE producing B-cells upon AIT is believed 
to be orchestrated mainly by allergen specific regulatory Tregs secreting IL-10 
(20). It is possible that the increase in lymph node derived effector memory cells 
is partly constituted of newly induced allergen specific Treg cells on the way to 
migrate to the periphery. One can also speculate that the increased level of central 
memory T-cells seen are in part allergen specific long-lived memory cells residing 
in the lymph nodes prepared to proliferate at a recall signal e g during the pollen 
season. However, the low amount of lymph node material available after aspira-
tion limited the analyses that could be performed.
Previous studies have investigated changes in T-cells in blood after ILIT. In a study 
of modified cat-dander allergen increased activation and proliferation of T-cells 
was seen 9 weeks after the start of the treatment (1 week after the last injection). 
The T-cells then turned unresponsive for allergen stimulation 1 year after  treatment. 
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Moreover, reduced amounts of allergen specific T-cells, increased levels of IL-10 
and FOXP3 were demonstrated (79). This study is special since it involved a 
transporter molecule to enhance intracellular signaling and therefore the same 
immunological changes can perhaps not be expected in other trials. Nevertheless, 
other favorable T-cell changes were reported in a pilot study of grass or birch- ILIT, 
where the levels of Th2 cells decreased and Treg cells and IL-10 increased during 
the treatment (54). A cedar tree ILIT trial searched for Treg induction after the 
third pollen season but could not identify any long-term changes (123). In a short 
dose-interval ILIT-study without signs of clinical improvement, reduced levels of 
IFN-γ was noted, suggesting a reduction of Th1 activation (61).
5.3.3 Basophils
In an attempt to characterize a third domain of tolerogenic response after ILIT, 
analyses of basophil characteristics were performed (paper IV). The basophils in 
the active ILIT group exhibited a low density of the high affinity receptor FcεR1 on 
the surface, and a corresponding low density of membrane bound IgE. Expression 
of FcεR1 on basophils is known to be induced at higher IgE levels in serum (105). 
The timothy specific IgE levels were higher in the non-AIT treated group, con-
sequently, our findings could be a result of this correlation. On the other hand, a 
recent study that characterized the FcεR1 on basophils during SLIT, did not find 
any difference in the expression of FcεR1 in AR-patients with low disease sever-
ity and low specific IgE levels, compared to a subgroup with more pronounced 
symptoms (105). Moreover, the transient increase in specific IgE upon SLIT did 
not correspond with an increase in FcεR1 expression during the first year of treat-
ment. Reasons for the discrepancies between our results and the findings in the 
mentioned study, might be attributed to the long-term treatment effect after ILIT, 
disparities in IgE levels and differences in the timing of the sampling.
We also performed a simplified basophil reactivity test (paper IV). This revealed 
a trend towards a lower degree of CD63 expression upon timothy stimulation in 
the active ILIT group than the non AIT-treated group. However, the relevance 
of this finding is uncertain since, in addition to not being significant, it was only 
measured after stimulation with one allergen concentration and not as a series of 
dilutions (103). The concentration chosen (500 SQ-U) is relatively high, leading 
to a high degree of activation among most sensitized patients. Stimulation with 
lower allergen concentrations might have demonstrated more prominent differences, 
based on the typical dose-response curve seen in BAT(128). We did not have any 
baseline values of the basophil reactivity and could not determine longitudinal 
changes, which is another limitation. 
50
Basophil reactivity testing can be used in allergy diagnostic and reduced reactivity 
is often seen early in SCIT, predicting symptom relieving effects (20, 103). In a 
previous ILIT study of grass, the basophil activation was not changed during the 
treatment or directly after the pollen season (53). This might be explained by fac-
tors associated with the exposure to allergen during treatment and soon after the 
pollen season. It might also indicate that the mechanism in ILIT differs, at least 
partly, from SCIT and does not involve basophil changes (53). 
5.3.4 DCs
DCs residing in the tonsils are believed to play a pivotal role in tolerance develop-
ment during SLIT (20). This is supported by findings of clusters of DCs and Tregs 
in the tonsils and the capacity of DCs to induce allergen specific Treg cells (129). 
We investigated the role of DCs in the ILIT de novo-3000 study. Discouragingly, 
the modest dose increase from 1000 to 3000 SQ-U did not show any clinical 
benefits. The DCs in the lymph nodes did exhibit increased level of activation 
characterized as expression of CD80, CD86 and CD141. However, the latter is 
attributed to Th2 activating properties (130) which is in line with the lack of a 
clinical improvement. 
5.3.5 Lack of clinical effect of 3000 SQ-U
There were no signs of clinical improvement in ILIT de novo- 3000. This was 
unexpected since the use of high allergen doses in conventional AIT generally is 
believed to produce a better symptom relief (111). This outcome also stands in 
contrast to the improvement induced by up-dosing in ILIT after SCIT- 10 000. It 
seems that this does not apply to unvaccinated patients. In some way the allergen 
dose might be too high to be favorably processed inside the lymph node when not 
actively transported to the site by antigen presenting cells. The aluminum hydroxide 
adjuvant in Alutard® when given in larger amounts might be too immunogenic. 
Alum has been shown to have Th2- skewing properties (131), potentially coun-
teracting tolerance induction. The role of alum in ILIT has not been described, it 
might be either unnecessary in ILIT, or crucial for the immunogenicity. Further, 
allergen specific B-cells residing in the lymph nodes might take up allergen after 
injection. When presenting very high amounts of antigen, the B-cells might be 
excluded from entering the follicular zones to proliferate and instead become 
anergic, in analogy with the peripheral selection process concerning elimination 
of self-antigens (132). 
Taken together, it is tempting to conclude that both an optimal dose and a well 
selected time interval is necessary for a positive outcome of ILIT. A too high dose 
or a too short time interval might be decremental. It is also important to notice 
that time and dose is closely related. A shorter time interval results in a higher 
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effective dose per week. Hence, our lack of symptom relief with the a higher 
ILIT dose can be related to the outcome in the study of Witten M, et al. 2013. 
They failed to demonstrate clinical effects despite allergen specific IgG4 induc-
tion (61). This trial used the same doses as most other ILIT-studies, 1000 SQ-U, 
but shortened the dose intervals to 2 weeks, leading to a higher allergen dose per 
time unit. Hypothetically, a dose increase in ILIT should be accompanied with 
a prolongation of the dose interval beyond 4 weeks. This could allow periods of 
low allergen content in the lymph node which has been speculated to be important 
for tolerance development in ILIT (62). This does not provide any explanation to 
the positive clinical improvement in ILIT after SCIT- 10 000. In some way, the 
previous SCIT treatment seems to have primed the immune system to be ready 
for tolerogenic responses at ILIT.
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6 CONCLUSIONS
- ILIT with birch or grass allergen given in three doses of 1000 SQ-U with one 
month apart seems safe among young patients with well-controlled asthma. 
Two allergens, birch and grass, can be given concomitantly using the same 
schedule. Higher doses of ILIT (1000- 3000- 10 000 SQ-U grass) can be given 
as add-on in previously SCIT vaccinated patients. However, the same sched-
ule causes severe systemic problems in unvaccinated patients, hence doses 
exceeding 3000 SQ-U should not be used. 
- An improvement of allergic asthma symptoms as a result of ILIT among 
patients with already well controlled disease was not possible to detect.
- Three ILIT-injections of 1000 SQ-U with birch and grass allergen given con-
comitantly reduce the symptoms at nasal grass allergen provocation and the 
need for seasonal symptom ameliorating medication.
- ILIT with grass allergen in escalating doses of 1000- 3000- 10 000 SQ-U after 
SCIT reduces the combined symptoms and medication scores. A schedule of 
1000- 3000- 3000 SQ-U in previously unvaccinated patients failed to induce 
any form of clinical improvement.
- A 5-6-years follow up of patients treated with grass and birch concomitantly 
(1000- 1000- 1000 SQ-U) revealed remaining low seasonal combined symp-
toms and medications scores, reduced grass specific IgE levels and produced 
a small sustained increase in grass specific IgG4. Altogether this indicates the 
possibility of long-term clinical effects.
- A short termed positive clinical outcome was associated with an increase in 
allergen specific serum IgG4 levels, an amplification in the proportion of mem-
ory T-cells in the lymph nodes with an augmented ratio of effector memory/
central memory T-cells. In addition, high levels of CD4+CD25++ regulatory 
effector memory T cells and CD4+CCR5+ Th1 type of central memory T-cells 
in blood was noted. A positive long termed outcome seems to be signified by 
an increased proportion of B-cells and memory CD4+ T-cells in the lymph 
nodes, in combination with reduced grass specific IgE levels in serum.
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7 POPULÄRVETENSKAPLIG SAMMAN-
FATTNING PÅ SVENSKA
Allergisk rinokonjunktivit (AR), eller ”hösnuva”, är en vanlig sjukdom i västvärl-
den. Närmare 40% av den yngre delen av befolkningen är drabbad. Hos den som 
drabbats utlöser i grunden harmlösa ämnen, som pollen, pälsdjur och kvalster, en 
allergisk reaktion relaterad till förekomst av IgE-antikroppar. Rinnande och kli-
ande ögon samt snuva, nysningar och nästäppa utgör sjukdomens huvudsymptom. 
Inte sällan förekommer också symptom på periodisk allergisk astma. Många med 
AR lider dessutom av påtaglig trötthet, något som varit känt sedan länge men vars 
betydelse ofta har negligerats. AR medför försämrad livskvalitet med en negativ 
påverkan på arbete, studier, sömn och socialt liv. Vår grupp har i tidigare studier 
beräknat att AR kostar det svenska samhället drygt 13 miljarder kronor årligen. 
AR behandlas vanligen med antihistamintabletter och kortisonnässpray. Flera 
undersökning visar dock att en stor del av patienterna inte är helt nöjda med effekten 
av denna behandling. Speciellt gäller detta livskvalitetssänkande symptom som 
trötthet. En mindre del av AR patienterna blir föremål för allergenspecifik immun-
terapi (AIT), s k allergivaccination. Detta är den enda behandling som förutom 
att den har effekt på symptomen, inklusive trötthet, också påverkar sjukdomens 
långsiktiga utveckling i positiv riktning.  
Vid AIT ges successivt ökande doser av det ämne man är allergisk mot (t ex björk, 
gräs eller kvalster), som injektion under huden eller som en tablett under tungan. 
Behandlingseffekten är hos flertalet mycket god och den symptomlindrande effekten 
varar vanligen flera år efter avslutad kur. Dock är det en tidskrävande behandling 
med upp emot 50 besök på sjukhuset för sprutor under tre till fem år, eller tabletter 
dagligen under tre år. Allergiska biverkningar förekommer. Vid tablettbehandling är 
klåda och svullnad under tungan vanligt och vid injektionsbehandling finns en risk 
för kraftig allergisk reaktion som astma, nässelutslag och, även om det är mycket 
ovanligt, allergisk chock. Dessutom är tillgången till allergikliniker begränsad så 
sammantaget är därför AIT en underutnyttjad terapiform.
Intralymfatisk immunterapi (ILIT) är ett nytt sätt att ge AIT som under senare tid 
vunnit insteg bland de allergiforskande kliniskt aktiva läkare som strävar att utveckla 
mer användarvänliga former av AIT. Med vägledning av ultraljud injiceras aller-
genet rakt in i en av ljumskens lymfkörtlar, där det kan utöva en direkt verkan på 
immunförsvaret. Med endast tre injektioner under åtta veckors tid har man erhållit 
en god symtomförbättring som väl motsvarar den man ser vid konventionell AIT. 
Eftersom det räcker med en mycket låg dos när allergen levereras direkt i lymf-
körteln, är risken för biverkningar dock påtagligt lägre än vid konventionell AIT.
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Den här avhandlingen syftade till att fortsätta undersöka ILIT genom att kartlägga 
säkerhet och effekter vid allergisk astma och vid injektion av mer än ett allergen 
samtidigt, liksom effekterna av en ökad dos av allergen. Vidare studerades om 
behandling med ILIT ger några kvarstående positiva effekter på allergisymptomen 
5–6 år efter avslutad terapi. För att möjliggöra en god utvärdering av effekten lot-
tades patienter till behandling med ILIT eller placebo.
I det första delarbetet såg vi att ILIT vid björk- och gräspollenallergi kan ges från 
16 års ålder och att samsjuklighet med välkontrollerad astma inte ökade risken 
för biverkningar. Användningen av symptomlindrande mediciner under pollen-
säsongen minskade första året och efter en så kallad boosterdos det andra året 
minskade medicinförbrukningen ytterligare. IgG4, som är en typ av antikroppar 
som motverkar den allergiska reaktionen, ökade som tecken på att tolerans mot 
allergenen utvecklats.
I den andra studien genomfördes samtidiga intralymfatiska injektioner av björk- 
och gräsallergen. Behandlingen gav endast milda biverkningar. Effekten mättes 
med näsprovokation, där gräspollen sprayades in i näsan. De patienter som hade 
fått aktiv ILIT reagerade med mindre symptom under testet än de patienter som 
behandlats med placebo. Vidare minskade medicinförbrukningen under pollen-
säsongen, IgG4 ökade och en typ av vita blodkroppar som verkar inflammations-
dämpande, så kallade regulatoriska T-celler, ökade.
Delarbete tre bestod av två studier där vi undersökte om högre doser av ILIT 
kunde ge bättre effekt. I den första studien gavs ILIT i ett stegrande schema till 
patienter som nyligen fått konventionell AIT med injektioner under huden, och 
som därmed redan från början hade ett visst skydd mot allergiska biverkningar. 
Dosökningen kunde genomföras utan några allvarliga reaktioner och under pol-
lensäsongen därpå hade patienterna mindre symptom och rapporterade en lägre 
medicinförbrukning. I den andra delstudien testades samma dosökning hos patienter 
med gräsallergi som inte tidigare behandlats med AIT. Doshöjning upp till 5000 
SQ-U (standardiserade enheter) gav akuta, mycket kraftiga allergiska reaktioner 
som kunde behandlas snabbt men dosupptrappning i resterande del av studien 
avbröts. Hos de patienter som erhållit en måttlig dosökning upp till 3000 SQ-U 
sågs överraskande nog ingen förbättring av symptomen. 
I det sista delarbetet följde vi upp de patienter som i delarbete II erhållit ILIT mot 
björk- och gräspollenallergi, 5–6 år efter behandlingen. Näsprovokationen, som 
året efter vaccinationen visat en reducerad symptomprofil, gav nu åter lika mycket 
symptom som före behandlingen. Dock var antalet rapporterade symptom och 
mängden använd allergimedicin under pollensäsongen lägre än hos en motsva-
rande kontrollgrupp av allergiska patienter som inte tidigare erhållit AIT. Vidare 
var halten av IgE-antikroppar mot gräs lägre och en typ av vita blodkroppar, så 
kallade T-minnesceller, i lymfkörtlarna högre. 
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Sammanfattningsvis belyser den här avhandlingen flera nya aspekter av ILIT. 
Behandlingen kan ges vid välbehandlad allergisk astma och med två allergen 
samtidigt. Hos patienter som nyligen erhållit konventionell AIT kan ILIT ge 
ytterligare symtomförbättring. Dosökning av ILIT utan föregående konventionell 
AIT är riskabel och verkar inte ge mer symptomlindring än lägre doser. Ökade 
doser bör därför troligen undvikas. Prover från blod och lymfkörtlar visade att 
ILIT motverkar några av de mekanismer i immunförsvaret som orsakar allergiska 
symptom och att det är möjligt att effekten av genomförd terapi varar i upp till 5 år.
Om ILIT kan utvecklas vidare, med mer kunskap om optimala doser och antal 
injektioner, kan den komma att utgöra ett attraktivt behandlingsalternativ vid 
AR. Med endast tre sjukhusbesök under en jämförelsevis kort period, skulle ILIT 
kunna erbjudas betydligt fler patienter än de som idag kan erhålla konventionell 
AIT, dessutom till en lägre kostnad för sjukvården. 
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